

# ERA-EDTA Registry



## Annual Report 2001

**Suggested citation**

ERA-EDTA Registry: ERA-EDTA Registry 2001 Annual Report. Academic Medical Center, Amsterdam, The Netherlands, June 2003.

## **ERA-EDTA Registry**

Dept. of Medical Informatics  
Academic Medical Center, J2-254  
PO Box 22700  
1100DE Amsterdam  
The Netherlands

Telephone +31 20 566 7637

Fax +31 20 691 9840

E-mail [erareg@amc.uva.nl](mailto:erareg@amc.uva.nl)

Website [www.era-edta-reg.org](http://www.era-edta-reg.org)

## **ERA-EDTA Registry Committee**

JD Briggs, chairman  
G Colasanti, Italy  
T Feest, United Kingdom  
C Grönhagen-Riska, Finland  
AJ van der Heijden, The Netherlands  
HJ Schober-Halstenberg, Germany  
K Simpson, Scotland  
B Stengel, France  
D Tsakiris, Greece  
K Verrier-Jones, United Kingdom

## **Registry Office Staff**

S Bos, database manager - website developer  
R Cornet, senior medical informatician  
FW Dekker, senior epidemiologist  
PCW van Dijk, medical informatician  
EF Guggenheim - van der Hout, secretary  
KJ Jager, managing director - epidemiologist  
VS Stel, epidemiologist

## Acknowledgements

The ERA-EDTA Registry would like to thank the patients and staff of all the dialysis and transplant units who have contributed data via their national and regional renal registries.

In addition, we would like to thank the following persons for their contribution to the work of the ERA-EDTA Registry.

---

### **Registry**

---

#### *For contribution to Section A*

---

Austria	R Kramar and HK Stummvoll
Belgium - Dutch-speaking	H Augustijn and J Donck
Belgium - French-speaking	F Collart
Denmark	H Løkkegaard
Finland	C Grönhagen-Riska and P Finne
Greece	GA Ioannidis
Iceland	P Ásmundsson
Norway	T Leivestad
Spain - Basque country	Á Magaz, J Aranzabal and I Lampreabe
Spain - Catalonia	M Clèries and E Vela
Spain - Valencia	O Zurriaga and MJ García Blasco
Sweden	S Schön
The Netherlands	F de Charro
United Kingdom - England/Wales	D Ansell and T Feest
United Kingdom - Scotland	K Simpson

---

#### *For contribution to Section B*

---

Bosnia - Herzegovina	E Mešić and H Resić
Croatia	S Čala
Czech Republic	J Lachmanova and F Lopot
Estonia	M Ots, M Luman and K Lilienthal
Germany	HJ Schober-Halstenberg and K Haas
Russia	N Tomilina and B Bikbov
Serbia and Montenegro	L Djukanovic and M Radovic
Tunesia	N Cherni and H Trimech
Turkey	K Serdengeçti and G Suleymanlar

---

The ERA-EDTA Registry is funded by the ERA-EDTA. The following companies have committed funds in the form of unrestricted educational grants to assist the ERA-EDTA in the financial support of the Registry: Amgen, Baxter, Fresenius Medical Care, Gambro, Hoffmann-La Roche, Hospal, Ortho-Biotech and Shire.

# Index

## I Introduction - 10

## II Methods - 11

## III Reference tables – SECTION A - 15

### **A1 AFFILIATED REGISTRY INFORMATION FOR 2001**

#### **Table A.1.1 - 16**

General population of the country/region and percent coverage of general population in 2001

#### **Table A.1.2 - 17**

Renal centres: total number of centres and number collaborating

### **A2 INCIDENT PATIENTS ACCEPTED FOR RRT IN 2001 (residents only) AT DAY 1**

#### **Table A.2.1 - 18**

Incident counts and percentage

*at day 1, by age and gender*

#### **Table A.2.2 - 19**

Gender, mean and median age of incident patients

*at day 1*

#### **Table A.2.3 - 20**

Incident rates per million population, unadjusted

*at day 1, by age and gender*

#### **Table A.2.4 - 21**

Incident rates per million population, unadjusted

*at day 1, by cause of renal failure*

#### **Table A.2.5 - 22**

Incident rates per million population, adjusted

*at day 1, by cause of renal failure, adjusted for age and gender*

### **A3 INCIDENT PATIENTS ACCEPTED FOR RRT IN 2001 (residents only) AT DAY 90**

#### **Table A.3.1 - 23**

Incident counts and percentage

*at day 90, by age and gender*

#### **Table A.3.2 - 24**

Gender, mean and median age of incident patients

*at day 90*

#### **Table A.3.3 - 25**

Incident rates per million population, unadjusted

*at day 90, by age and gender*

#### **Table A.3.4 - 26**

Incident rates per million population, unadjusted

*at day 90, by cause of renal failure*

**Table A.3.5 - 27**

Incident rates per million population, adjusted  
*at day 90, by cause of renal failure, adjusted for age and gender*

**Table A.3.6 - 28**

Incident counts  
*at day 90, by established therapy*

**Table A.3.7 - 29**

Incident rates per million population, unadjusted  
*at day 90, by established therapy*

**Table A.3.8 - 30**

Incident rates per million population, adjusted  
*at day 90, by established therapy, adjusted for age and gender*

**Table A.3.9 - 31**

Percentage of established therapy, unadjusted  
*at day 90*

**Table A.3.10 - 32**

Percentage of established therapy, unadjusted  
*at day 90, by age, gender and primary diagnosis*

**A4 PREVALENT PATIENTS ON RRT IN 2001 (residents only)**

**Table A.4.1 - 33**

Prevalence counts and percentage  
*prevalent patients on December 31, by age and gender*

**Table A.4.2 - 34**

Gender, mean and median age  
*prevalent patients on December 31*

**Table A.4.3 - 35**

Prevalence per million population, unadjusted  
*prevalent patients on December 31, by age and gender*

**Table A.4.4 - 36**

Prevalence per million population and percentage, unadjusted  
*prevalent patients on December 31, by cause of renal failure*

**Table A.4.5 - 37**

Prevalence per million population, adjusted  
*prevalent patients on December 31, by cause of renal failure, adjusted for age and gender*

**Table A.4.6 - 38**

Prevalence counts  
*prevalent patients on December 31, by established therapy*

**Table A.4.7 - 39**

Prevalence per million population, unadjusted  
*prevalent patients on December 31, by established therapy*

**Table A.4.8 - 40**

Prevalence per million population, adjusted  
*prevalent patients on December 31, by established therapy, adjusted for age and gender*

**Table A.4.9 - 41**

Percentage of established therapy, unadjusted  
*prevalent patients on December 31*

**Table A.4.10 - 42**

Percentage of established therapy, unadjusted  
*prevalent patients on December 31, by age, gender and primary diagnosis*

**Table A.4.11 - 43**

Patients living on a functioning graft, unadjusted  
*prevalent patients on December 31*

**A5 SURVIVAL PROBABILITY (residents only)**

**Patient Survival on Renal Replacement Therapy (RRT)**

**Table A.5.1 - 44**

90-day, one-, two- and five-year survival probabilities (cohort 1992-1996): Incident RRT patients, unadjusted  
*from day 1 to 90 days, one, two and five years, by age, gender and primary diagnosis*

**Table A.5.2 - 44**

90-day, one-, two- and five-year survival probabilities (cohort 1992-1996): Incident RRT patients, adjusted  
*from day 1 to 90 days, one, two and five years, adjusted for age, gender and primary diagnosis*

**Table A.5.3 - 45**

One-, two- and five-year survival probabilities (cohort 1992-1996): Incident RRT patients, unadjusted  
*from day 91 to one, two and five years + 90 days, by age, gender and primary diagnosis*

**Table A.5.4 - 45**

One-, two- and five-year survival probabilities (cohort 1992-1996): Incident RRT patients, adjusted  
*from day 91 to one, two and five years + 90 days, adjusted for age, gender and primary diagnosis*

**Table A.5.5 - 46**

90-day, one- and two-year survival probabilities (cohort 1995-1999): Incident RRT patients, unadjusted  
*from day 1 to 90 days, one and two years, by age, gender and primary diagnosis*

**Table A.5.6 - 46**

90-day, one- and two-year survival probabilities (cohort 1995-1999): Incident RRT patients, adjusted  
*from day 1 to 90 days, one and two years, adjusted for age, gender and primary diagnosis*

**Table A.5.7 - 47**

One- and two-year survival probabilities (cohort 1995-1999): Incident RRT patients, unadjusted  
*from day 91 to one and two years + 90 days, by age, gender and primary diagnosis*

**Table A.5.8 - 47**

One- and two-year survival probabilities (cohort 1995-1999): Incident RRT patients, adjusted  
*from day 91 to one and two years + 90 days, adjusted for age, gender and primary diagnosis*

**Patient Survival on Dialysis**

**Table A.5.9 - 48**

90-day, one-, two- and five-year survival probabilities (cohort 1992-1996): Incident dialysis patients, unadjusted  
*from day 1 to 90 days, one, two and five years, by age, gender and primary diagnosis*

**Table A.5.10 - 48**

90-day, one-, two- and five-year survival probabilities (cohort 1992-1996): Incident dialysis patients, adjusted  
*from day 1 to 90 days, one, two and five years, adjusted for age, gender and primary diagnosis*

**Table A.5.11 - 49**

One-, two- and five-year survival probabilities (cohort 1992-1996): Incident dialysis patients, unadjusted  
*from day 91 to one, two and five years + 90 days, by age, gender and primary diagnosis*

**Table A.5.12 - 49**

One-, two- and five-year survival probabilities (cohort 1992-1996): Incident dialysis patients, adjusted  
*from day 91 to one, two and five years + 90 days, adjusted for age, gender and primary diagnosis*

**Table A.5.13 - 50**

90-day, one- and two-year survival probabilities (cohort 1995-1999): Incident dialysis patients, unadjusted  
*from day 1 to 90 days, one and two years, by age, gender and primary diagnosis*

**Table A.5.14 - 50**

90-day, one- and two-year survival probabilities (cohort 1995-1999): Incident dialysis patients, adjusted from day 1 to 90 days, one and two years, adjusted for age, gender and primary diagnosis

**Table A.5.15 - 51**

One- and two-year survival probabilities (cohort 1995-1999): Incident dialysis patients, unadjusted from day 91 to one and two years + 90 days, by age, gender and primary diagnosis

**Table A.5.16 - 51**

One- and two-year survival probabilities (cohort 1995-1999): Incident dialysis patients, adjusted from day 91 to one and two years + 90 days, adjusted for age, gender and primary diagnosis

**Patient Survival after First Transplant (cadaver donor)**

**Table A.5.17 - 52**

One-, two- and five-year survival probabilities (cohort 1992-1996): First transplant patients (cadaver donor), unadjusted from day of transplant to one, two and five years, by age, gender and primary diagnosis

**Table A.5.18 - 52**

One-, two- and five-year survival probabilities (cohort 1992-1996): First transplant patients (cadaver donor), adjusted from day of transplant to one, two and five years, adjusted for age, gender and primary diagnosis

**Table A.5.19 - 53**

One- and two-year survival probabilities (cohort 1995-1999): First transplant patients (cadaver donor), unadjusted from day of transplant to one and two years, by age, gender and primary diagnosis

**Table A.5.20 - 53**

One- and two-year survival probabilities (cohort 1995-1999): First transplant patients (cadaver donor), adjusted from day of transplant to one and two years, adjusted for age, gender and primary diagnosis

**Patient Survival after First Transplant (living donor)**

**Table A.5.21 - 54**

One-, two- and five-year survival probabilities (cohort 1992-1996): First transplant patients (living donor), unadjusted from day of transplant to one, two and five years, by age, gender and primary diagnosis

**Table A.5.22 - 54**

One-, two- and five-year survival probabilities (cohort 1992-1996): First transplant patients (living donor), adjusted from day of transplant to one, two and five years, adjusted for age, gender and primary diagnosis

**Table A.5.23 - 55**

One- and two-year survival probabilities (cohort 1995-1999): First transplant patients (living donor), unadjusted from day of transplant to one and two years, by age, gender and primary diagnosis

**Table A.5.24 - 55**

One- and two-year survival probabilities (cohort 1995-1999): First transplant patients (living donor), adjusted from day of transplant to one and two years, adjusted for age, gender and primary diagnosis

**Graft Survival after First transplant (cadaver donor)**

**Table A.5.25 - 56**

One-, two- and five-year survival probabilities (cohort 1992-1996): First graft (cadaver donor), unadjusted from day of transplant to one, two and five years, by age, gender and primary diagnosis

**Table A.5.26 - 56**

One-, two- and five-year survival probabilities (cohort 1992-1996): First graft (cadaver donor), adjusted from day of transplant to one, two and five years, adjusted for age, gender and primary diagnosis

**Table A.5.27 - 57**

One- and two-year survival probabilities (cohort 1995-1999): First graft (cadaver donor), unadjusted from day of transplant to one and two years, by age, gender and primary diagnosis

**Table A.5.28 - 57**

One- and two-year survival probabilities (cohort 1995-1999): First graft (cadaver donor), adjusted from day of transplant to one and two years, adjusted for age, gender and primary diagnosis



### **Graft Survival after First Transplant (living donor)**

#### **Table A.5.29 - 58**

One-, two- and five-year survival probabilities (cohort 1992-1996): First graft (living donor), unadjusted  
*from day of transplant to one, two and five years, by age, gender and primary diagnosis*

#### **Table A.5.30 - 58**

One-, two- and five-year survival probabilities (cohort 1992-1996): First graft (living donor), adjusted  
*from day of transplant to one, two and five years, adjusted for age, gender and primary diagnosis*

#### **Table A.5.31 - 59**

One- and two-year survival probabilities (cohort 1995-1999): First graft (living donor), unadjusted  
*from day of transplant to one and two years, by age, gender and primary diagnosis*

#### **Table A.5.32 - 59**

One- and two-year survival probabilities (cohort 1995-1999): First graft (living donor), adjusted  
*from day of transplant to one and two years, adjusted for age, gender and primary diagnosis*

## **IV Reference tables – SECTION B - 60**

### **B1 AFFILIATED REGISTRY INFORMATION FOR 2001**

#### **Table B.1.1 - 61**

General population of the country/region and percent coverage of general population in 2001

#### **Table B.1.2 - 62**

Renal centres: total number of centres and number collaborating

### **B2 INCIDENT PATIENTS ACCEPTED FOR RRT IN 2001 (residents only) AT DAY 1**

#### **Table B.2.1 - 63**

Incident counts and incident rates per million population, unadjusted  
*at day 1*

#### **Table B.2.2 - 64**

Gender, mean and median age of incident patients  
*at day 1*

#### **Table B.2.3 - 65**

Incident rates per million population, adjusted  
*at day 1, adjusted for age and gender*

#### **Table B.2.4 - 66**

Incident rates per million population and percentage, unadjusted  
*at day 1, by cause of renal failure*

### **B3 INCIDENT PATIENTS ACCEPTED FOR RRT IN 2001 (residents only) AT DAY 90**

#### **Table B.3.1 - 67**

Incident counts and incident rates per million population, unadjusted  
*at day 90*

#### **Table B.3.2 - 68**

Gender, mean and median age of incident patients  
*at day 90*

#### **Table B.3.3 - 69**

Incident rates per million population, adjusted  
*at day 90, adjusted for age and gender*

**Table B.3.4 - 70**

Incident rates per million population and percentage, unadjusted  
*at day 90, by cause of renal failure*

**Table B.3.5 - 71**

Incident counts  
*at day 90, by established therapy*

**Table B.3.6 - 72**

Incident rates per million population, unadjusted  
*at day 90, by established therapy*

**Table B.3.7 - 73**

Percentage of established therapy, unadjusted  
*at day 90*

**B4 PREVALENT PATIENTS ON RRT IN 2001 (residents only)**

**Table B.4.1 - 74**

Prevalent counts and per million population, unadjusted  
*prevalent patients on December 31*

**Table B.4.2 - 75**

Gender, mean and median age  
*prevalent patients on December 31*

**Table B.4.3 - 76**

Prevalence per million population, adjusted  
*prevalent patients on December 31, adjusted for age and gender*

**Table B.4.4 - 77**

Prevalence per million population and percentage, unadjusted  
*prevalent patients on December 31, by cause of renal failure*

**Table B.4.5 - 78**

Prevalence counts  
*prevalent patients on December 31, by established therapy*

**Table B.4.6 - 79**

Prevalence per million population, unadjusted  
*prevalent patients on December 31, by established therapy*

**Table B.4.7 - 80**

Percentage of established therapy, unadjusted  
*prevalent patients on December 31*

**Table B.4.8 - 81**

Renal transplants, number and percentage  
*by donor type*

## **I Introduction**

This is the second year in which the Amsterdam based ERA-EDTA Registry has published an annual report. Section A of this report includes tables with 2001 data based on the analyses of data sets received from national and regional registries collecting individual patient data that are included in the ERA-EDTA Registry database. These data are published after receipt of the data sets and subsequent analysis by the Registry office and the following permission for publication from the country involved.

Section B relates to the countries collecting individual patient data, centre questionnaire data or information from health authorities. Their data are not included in the ERA-EDTA Registry database. These countries complete the tables themselves and return them to the ERA-EDTA Registry office for inclusion in this annual report.

## II Methods

### Section A

The tables in this section are based on the analyses of data sets received from national and regional registries collecting individual patient data, which are included in the ERA-EDTA Registry database.

The databases serving as a basis for the analyses were received on the dates shown in the following table.

<b>Registry</b>	<b>Date</b>
Austria	19 June 2002
Belgium – Dutch-speaking	6 January 2003
Belgium – French-speaking	28 April 2003
Denmark	6 January 2003
Finland	19 December 2002
Greece	6 February 2003
Iceland	3 April 2003
Norway	3 February 2003
Spain – Basque country	19 March 2003
Spain – Catalonia	17 October 2002
Spain – Valencia	10 September 2002
Sweden	8 July 2002
The Netherlands	25 March 2003
United Kingdom - England/Wales	28 March 2003
United Kingdom - Scotland	3 April 2003

Registry data are subject to continuous alteration and improvement. Small differences between ERA-EDTA Registry data and the data presented in the national/regional registry's own annual reports may therefore result from different times of data extraction.

### ***Differences in data collection between collaborating registries and inclusion of their data into the ERA-EDTA Registry database***

In the comparison of data between registries it should be recognised that there may be small differences between registries in definitions and in the collection of their data. The different registries do not for example collect data at the same level of detail, especially with regard to the different subtypes of the treatment modalities. Also, registries may handle temporary changes in the treatment modality of the individual patient differently.

The data from England/Wales (United Kingdom) exclude patients younger than 18 years of age in the data sets provided to the ERA-EDTA Registry. Inclusion of those would add 2 pmp to the overall UK incidence rate and 12 pmp to the UK prevalence. In addition, it should be noted that the prevalence figures produced by the UK Renal Registry are slightly higher than those produced by the ERA-EDTA Registry. This is due to the fact that the UK Renal Registry calculates prevalence rates from the electronic quarterly data returns (which are not part of the ERA-EDTA Registry data set) rather than from the timeline which can be incomplete for some patients.

## ***Incidence and prevalence***

The incidence tables refer to all patients who started RRT for ESRD in 2001 and the prevalence tables to all patients who were alive and on RRT on 31 December 2001. General population data for the year 2001, provided by Eurostat, the national bureaus of statistics or the national or regional registry, served as the population base.

The grouping of renal diseases is provided in Appendix 1.

For the adjustment of incidence and prevalence for age and gender we used the age and gender distribution of the European population of 1995 as provided by Eurostat.

## ***Survival analysis***

For the analysis of survival data we used two five-year cohorts:

- 1992-1996 - for the presentation of 90-day (for survival on RRT and on dialysis), one-, two- and five-year survival probabilities. These analyses were based on data from Austria, Basque Country (Spain), Catalonia (Spain), Denmark, Dutch-speaking Belgium, Finland, French-speaking Belgium, Greece, Iceland, Norway, Scotland (United Kingdom), Sweden, The Netherlands and Valencia (Spain).
- 1995-1999 - for the presentation of 90-day (for survival on RRT and on dialysis), one- and two-year survival probabilities. These analyses were based on data from Austria, Basque Country (Spain), Catalonia (Spain), Denmark, Dutch-speaking Belgium, England/Wales (United Kingdom), Finland, French-speaking Belgium, Greece, Iceland, Norway, Scotland (United Kingdom), Sweden, The Netherlands and Valencia (Spain).

With regard to the inclusion of data, some further comments need to be made. The data were used from the date from which they were available, which in a small number of cases was later than the first cohort year, this being due to the fact that the national or regional registry was established later. Survival was analysed from day 1 and from day 91 onwards for those patients alive and on RRT on those days. All patients had the opportunity to complete the entire follow-up period with the exception of patients starting in the last 90 days of a cohort in a survival analysis from day 91.

For the different types of survival analysis we defined the following events and censoring.

<i>Survival type</i>	<i>Event</i>	<i>Censoring</i>
Patients on renal replacement therapy	Death of patient	Recovery of renal function Loss to follow-up End of follow-up time
Patients on dialysis	Death of patient	Transplantation Recovery of renal function Loss to follow-up End of follow-up time
First transplant recipients	Death of patient	Loss to follow-up End of follow-up time
First graft	Death of patient Graft failure	Loss to follow-up End of follow-up time

As the ERA-EDTA Registry database is still growing with respect to the coverage of European countries, we chose to adjust for fixed parameters in our survival analyses. The values for adjustment are shown in the following table.

<i>Survival type</i>	<i>Age</i>	<i>Gender</i>	<i>Renal disease</i>
Patients on renal replacement therapy	60 years	60% male	DM - non DM 20/80
Patients on dialysis	60 years	60% male	DM - non DM 20/80
First transplant recipients (cadaver donor)	45 years	60% male	DM - non DM 10/90
First transplant recipients (living donor)	45 years	60% male	DM - non DM 10/90
First graft (cadaver donor)	45 years	60% male	DM - non DM 10/90
First graft (living donor)	45 years	60% male	DM - non DM 10/90

In unadjusted survival analysis the cells in the tables were left blank when there were less than 30 patients in that cell. In the adjusted survival analysis, cells with less than 30 events were left empty. The latter analysis excluded patients for whom age, gender, or primary renal disease was missing.

## **Section B**

These tables relate to countries collecting individual patient data, centre questionnaire data or information from health authorities. Their data are not included in the ERA-EDTA Registry database. The tables were completed by national and regional registries and sent to the ERA-EDTA Registry for inclusion in this annual report.

The incidence tables refer to all patients who started RRT for ESRD in 2001 and the prevalence tables to all patients who were alive and on RRT on 31 December 2001. General population data for the year 2001 were provided by the national or regional registries. For the adjustment of incidence and prevalence for age and gender they used the age and gender distribution of the European population of 1995.

## **Appendix 1 - Grouping of renal diseases**

Primary Renal Disease (PRD)	1994 code	1995 code	PRD Group
Glomerulonephritis; histologically NOT examined	10	10	I
Focal segmental glomerulosclerosis with nephrotic syndrome in children	11	11	I
IgA nephropathy (proven by immunofluorescence, not code 76 and not 85)	12	12	I
Dense deposit disease; membrano-proliferative GN; type II (proven by immunofluorescence and/or electron microscopy)	13	13	I
Membranous nephropathy	14	14	I
Membrano-proliferative GN; type I (proven by immunofluorescence and/or electron microscopy - not code 84 or 89)	15	15	I
Crescentic (extracapillary) glomerulonephritis (type I, II, III)	16	16	I
Focal segmental glomerulosclerosis with nephrotic syndrome in adults	17	17	I
Glomerulonephritis; histologically examined, not given above	19	19	I
Pyelonephritis – cause not specified	20	20	II
Pyelonephritis associated with neurogenic bladder	21	21	II
Pyelonephritis due to congenital obstructive uropathy with/without vesico-ureteric reflux	22	22	II
Pyelonephritis due to acquired obstructive uropathy	23	23	II

Primary Renal Disease (PRD)	1994 code	1995 code	PRD Group
Pyelonephritis due to vesico-ureteric reflux without obstruction	24	24	II
Pyelonephritis due to urolithiasis	25	25	II
Pyelonephritis due to other cause	29	29	II
Interstitial nephritis (not pyelonephritis) due to other cause, or unspecified (not mentioned above)	30	30	VII
Nephropathy (interstitial) due to analgesic drugs	31	31	VII
Nephropathy (interstitial) due to cis-platinum	32	32	VII
Nephropathy (interstitial) due to cyclosporin A	33	33	VII
Lead induced nephropathy (interstitial)		34	VII
Drug induced nephropathy (interstitial) not mentioned above	39	39	VII
Cystic kidney disease - type unspecified	40	40	VII
Polycystic kidneys; adult type (dominant)	41	41	III
Polycystic kidneys; infantile (recessive)	42	42	VII
Medullary cystic disease; including nephronophthisis	43	43	VII
Cystic kidney disease - other specified type	49	49	VII
Hereditary/Familial nephropathy - type unspecified	50	50	VII
Hereditary nephritis with nerve deafness (Alport's Syndrome)	51	51	VII
Cystinosis	52	52	VII
Primary oxalosis	53	53	VII
Fabry's disease	54	54	VII
Hereditary nephropathy - other specified type	59	59	VII
Renal hypoplasia (congenital) - type unspecified	60	60	VII
Oligomeganephronic hypoplasia	61	61	VII
Congenital renal dysplasia with or without urinary tract malformation	63	63	VII
Syndrome of agenesis of abdominal muscles (Prune Belly)	66	66	VII
Renal vascular disease - type unspecified	70	70	V
Renal vascular disease due to malignant hypertension	71	71	IV
Renal vascular disease due to hypertension	72	72	IV
Renal vascular disease due to polyarteritis	73	73	VII
Wegener's granulomatosis	74	74	VII
Glomerulonephritis related to liver cirrhosis	76	76	VII
Cryoglobulinaemic glomerulonephritis		78	VII
Renal vascular disease - due to other cause (not given above and not code 84-88)	79	79	V
Diabetes glomerulosclerosis or diabetic nephropathy - Type I	80	80	VI
Diabetes glomerulosclerosis or diabetic nephropathy - Type II	81	80	VI
Myelomatosis/light chain deposit disease	82	82	VII
Amyloid	83	83	VII
Lupus erythematosus	84	84	VII
Henoch-Schoenlein purpura	85	85	VII
Goodpasture's Syndrome	86	86	VII
Systemic sclerosis (scleroderma)	87	87	VII
Haemolytic Uraemic Syndrome (including Moschowitz Syndrome)	88	88	VII
Multi-system disease - other (not mentioned above)	89	89	VII
Tubular necrosis (irreversible) or cortical necrosis (different from 88)	90	90	VII
Tuberculosis	91	91	VII
Gout	92	92	VII
Nephrocalcinosis and hypercalcaemic nephropathy	93	93	VII
Balkan nephropathy	94	94	VII
Kidney tumour	95	95	VII
Traumatic or surgical loss of kidney	96	96	VII
Other identified renal disorders	99	99	VII
Chronic renal failure; aetiology uncertain	00	00	VIII

I Glomerulonephritis/sclerosis; II Pyelonephritis; III Polycystic kidneys, adult type; IV Hypertension ;V Renal vascular disease; VI Diabetes mellitus; VII Miscellaneous; VIII Unknown

### **III Reference tables – SECTION A**



Table A.1.1

**General population of the country/region and percent coverage of general population in 2001**

	<b>General population in thousands</b>	<b>% Coverage of general population</b>
Austria	8,065.5	100
Belgium, Dutch-speaking	5,952.6	100
Belgium, French-speaking	4,310.9	100
Denmark	5,355.1	100
Finland	5,194.9	100
Greece	10,964.0	100
Iceland	286.6	100
Norway	4,524.1	100
Spain, Basque country	2,068.4	100
Spain, Catalonia	6,219.5	100
Spain, Valencia	4,202.6	100
Sweden	8,909.1	100
The Netherlands	15,987.1	100
UK, England/Wales	52,041.9	69
UK, Scotland	5,062.0	100

Table A.1.2

**Renal centres: total number of centres and number collaborating**

	<b>Total number of renal centres</b>	<b>Number of renal centres collaborating with the registry</b>
Austria	60	60
Belgium, Dutch-speaking	27	27
Belgium, French-speaking	38	38
Denmark	15	15
Finland	31	31
Greece	114	114
Iceland	1	1
Norway	20	20
Spain, Basque country	12	12
Spain, Catalonia	44	44
Spain, Valencia	45	45
Sweden	66	66
The Netherlands	51	51
UK, England/Wales	63	38
UK, Scotland	11	11

Table A.2.1  
**Incident counts and percentage**  
*at day 1, by age and gender*

	All						0-19						20-44						45-64						65-74						75+					
	Men		Women		All		Men		Women		All		Men		Women		All		Men		Women		All		Men		Women		All							
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%						
Austria	663	100	434	100	1097	100	11	2	4	1	15	1	82	12	40	9	122	11	285	43	148	34	433	39	181	27	124	29	305	28	104	16	118	27	222	20
Belgium, Dutch-speaking	566	100	385	100	951	100	1	0	3	1	4	0	54	10	31	8	85	9	152	27	111	29	263	28	187	33	121	31	308	32	172	30	119	31	291	31
Belgium, French-speaking	395	100	338	100	733	100	8	2	3	1	11	2	39	10	39	12	78	11	121	31	101	30	222	30	115	29	100	30	215	29	112	28	94	28	206	28
Denmark	486	100	254	100	740	100	10	2	2	1	12	2	48	10	33	13	81	11	190	39	83	33	273	37	139	29	71	28	210	28	99	20	65	26	164	22
Finland	268	100	190	100	458	100	10	4	7	4	17	4	46	17	26	14	72	16	118	44	72	38	190	41	61	23	55	29	116	25	33	12	30	16	63	14
Greece	1106	100	687	100	1793	100	10	1	3	0	13	1	124	11	60	9	184	10	314	28	177	26	491	27	377	34	248	36	625	35	257	23	183	27	440	25
Iceland	12	100	10	100	22	100							4	33	2	20	6	27		5	50	5	23	6	50	1	10	7	32	2	17	2	20	4	18	
Norway	272	100	155	100	427	100	6	2	1	1	7	2	48	18	29	19	77	18	89	33	49	32	138	32	71	26	32	21	103	24	58	21	44	28	102	24
Spain, Basque country	165	100	80	100	245	100	2	1	3	4	5	2	22	13	10	13	32	13	58	35	27	34	85	35	51	31	26	33	77	31	32	19	14	18	46	19
Spain, Catalonia	584	100	324	100	908	100	7	1	5	2	12	1	71	12	42	13	113	12	165	28	77	24	242	27	176	30	87	27	263	29	165	28	113	35	278	31
Spain, Valencia	367	100	221	100	588	100	9	2	4	2	13	2	50	14	19	9	69	12	122	33	68	31	190	32	112	31	63	29	175	30	74	20	67	30	141	24
Sweden	723	100	384	100	1107	100	6	1	9	2	15	1	87	12	61	16	148	13	219	30	120	31	339	31	192	27	89	23	281	25	219	30	105	27	324	29
The Netherlands	982	100	618	100	1600	100	25	3	14	2	39	2	158	16	103	17	261	16	356	36	225	36	581	36	255	26	161	26	416	26	188	19	115	19	303	19
UK, England/Wales	2010	100	1181	100	3193	100	8	0	7	1	15	0	327	16	234	20	561	18	680	34	374	32	1054	33	545	27	336	28	882	28	450	22	230	19	681	21
UK, Scotland	291	100	222	100	513	100	11	4	5	2	16	3	42	14	30	14	72	14	89	31	51	23	140	27	80	27	73	33	153	30	69	24	63	28	132	26

*Percentages are row percentages  
Categories may not add up to total or to 100% because of missing values*

Table A.2.2

**Gender, mean and median age of incident patients***at day 1*

	All				Men				Women			
	%	Mean (years)	(SD)	Median (years)	%	Mean (years)	(SD)	Median (years)	%	Mean (years)	(SD)	Median (years)
Austria	100	62	(15.0)	64.2	60	60.6	(15.2)	62.5	40	64.6	(14.3)	67.5
Belgium, Dutch-speaking	100	66	(14.4)	69.6	60	66.1	(14.1)	69.2	40	66.8	(15.0)	70.4
Belgium, French-speaking	100	64	(16.2)	68.2	54	64.0	(16.5)	68.2	46	64.4	(15.9)	68.4
Denmark	100	62	(15.4)	65.2	66	62.2	(15.4)	64.7	34	62.8	(15.6)	66.2
Finland	100	57	(16.9)	61.0	59	56.8	(16.7)	59.7	41	58.1	(17.2)	63.3
Greece	100	65	(14.9)	68.4	62	64.1	(15.2)	67.8	38	66.0	(14.3)	69.5
Iceland	100	58	(18.4)	65.0	55	56.8	(21.5)	67.4	45	59.2	(14.9)	58.6
Norway	100	61	(17.3)	64.0	64	60.4	(17.3)	63.0	36	60.9	(17.3)	64.7
Spain, Basque country	100	61	(15.8)	65.4	67	61.8	(15.1)	65.6	33	60.3	(17.2)	64.9
Spain, Catalonia	100	64	(15.9)	68.3	64	63.7	(15.7)	67.8	36	65.2	(16.4)	69.3
Spain, Valencia	100	63	(16.2)	66.5	62	61.4	(16.6)	65.4	38	65.0	(15.2)	67.6
Sweden	100	64	(16.4)	67.1	65	64.5	(15.8)	67.8	35	61.6	(17.5)	65.4
The Netherlands	100	60	(16.6)	62.7	61	59.8	(16.6)	62.8	39	59.5	(16.6)	62.4
UK, England/Wales	100	61	(16.1)	64.7	63	61.7	(16.0)	64.8	37	60.2	(16.4)	64.0
UK, Scotland	100	62	(17.3)	66.4	57	61.1	(17.6)	65.6	43	63.3	(16.9)	67.9

Table A.2.3  
**Incident rates per million population, unadjusted**  
*at day 1, by age and gender*

	All			0-19			20-44			45-64			65-74			75+		
	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All
	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp
Austria	169.7	104.4	136.0	11.7	4.4	8.1	53.6	26.7	40.3	296.8	149.5	222.0	616.1	337.4	461.2	579.5	292.1	380.5
Belgium, Dutch-speaking	192.8	127.6	159.8	1.4	4.5	2.9	50.1	29.7	40.0	206.7	152.9	180.0	697.3	387.8	530.8	1088.1	439.8	678.8
Belgium, French-speaking	189.6	151.7	170.0	14.9	5.8	10.4	50.5	51.1	50.8	246.2	198.2	221.8	668.5	454.2	548.2	1029.1	427.6	626.8
Denmark	183.6	93.8	138.2	15.3	3.2	9.4	49.9	35.4	42.8	272.4	120.0	196.5	719.8	320.8	506.7	709.0	271.2	432.3
Finland	105.6	71.5	88.2	15.5	11.3	13.5	52.2	30.7	41.7	166.8	101.2	133.9	313.9	226.0	265.0	297.0	125.8	180.2
Greece	203.6	124.2	163.5	8.0	2.6	5.4	59.1	29.7	44.7	247.9	134.7	190.3	700.8	396.4	537.1	896.5	432.7	620.1
Iceland	83.7	69.9	76.8				74.3	37.9	56.3		170.1	83.8	685.8	104.3	381.8	320.9	228.3	266.8
Norway	119.2	69.1	94.4	10.5	1.7	6.0	61.1	35.6	48.2	167.5	90.2	128.4	411.1	212.1	318.3	261.8	336.7	289.6
Spain, Basque country	163.5	75.5	118.4	10.9	17.2	14.0	52.6	24.4	38.6	228.8	102.8	164.7	509.5	223.5	355.7	602.3	144.8	307.1
Spain, Catalonia	192.0	102.0	146.0	11.3	8.5	9.9	57.6	35.1	46.5	226.8	102.0	163.2	623.7	257.8	424.5	928.9	371.6	577.1
Spain, Valencia	178.1	103.2	139.9	20.2	9.5	15.0	58.6	22.9	41.0	263.7	140.3	200.6	614.6	285.4	434.3	649.3	356.7	467.2
Sweden	164.0	85.3	124.3	5.5	8.6	7.0	57.8	42.2	50.2	189.8	105.8	148.2	555.2	226.5	380.4	714.5	215.7	408.4
The Netherlands	124.1	76.5	100.1	12.5	7.3	10.0	52.2	35.1	43.8	178.8	115.3	147.4	459.8	248.5	346.0	554.9	181.6	311.7
UK, England/Wales	115.0	64.1	88.9	1.7	1.6	1.7	52.5	36.6	44.5	160.8	86.5	123.3	386.2	209.7	292.7	450.0	133.5	250.1
UK, Scotland	119.6	84.4	101.3	17.6	8.4	13.1	48.0	32.6	40.1	146.7	80.7	113.1	399.9	296.8	343.0	550.7	269.7	367.8

Table A.2.4  
**Incident rates per million population, unadjusted**  
*at day 1, by cause of renal failure*

	Cause of renal failure																							
	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing	
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Type I	Type II	Both					Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp
Austria	136.0	100	19.1	14	6.9	5	5.8	4	6.0	4	37.7	28	43.6	32	9.9	7	14.1	10	19.2	14	17.1	13		
Belgium, Dutch-speaking	159.8	100	17.8	11	8.7	5	6.4	4	14.8	9	22.8	14	37.6	24	13.1	8	22.5	14	33.8	21	19.7	12		
Belgium, French-speaking	170.0	100	20.6	12	14.2	8	8.1	5	5.3	3	30.2	18	35.5	21	22.7	13	12.8	8	43.8	26	11.8	7		
Denmark	138.2	100	15.5	11	10.1	7	8.8	6	15.9	11	15.3	11	31.2	23	14.4	10	1.3	1	31.7	23	25.2	18		
Finland	88.2	100	11.7	13	6.7	8	8.9	10	11.7	13	17.3	20	29.1	33	3.7	4	0.4	0	17.9	20	9.8	11		
Greece	163.5	100	21.5	13	11.3	7	8.1	5	16.4	10	27.5	17	43.9	27	18.5	11	3.7	2	14.6	9	41.9	26		
Iceland	76.8	100	7.0	9	3.5	5			14.0	18			14.0	18	27.9	36			20.9	27	3.5	5		
Norway	94.4	100	17.7	19	9.5	10	6.6	7	7.5	8	6.0	6	13.5	14	22.3	24	1.5	2	19.9	21	3.3	4		
Spain, Basque country *	118.4	100																						
Spain, Catalonia	146.0	100	21.7	15	15.6	11	11.6	8	5.5	4	24.1	17	29.6	20	15.1	10	12.1	8	14.6	10	25.6	18		
Spain, Valencia	139.9	100	18.3	13	15.2	11	9.0	6					20.2	14	24.0	17	4.8	3	14.5	10	33.8	24		
Sweden	124.3	100	18.3	15	5.2	4	6.7	5	13.2	11	18.1	15	31.3	25	11.9	10	12.1	10	25.9	21	12.6	10		
The Netherlands	100.1	100	10.1	10	5.9	6	6.5	7	5.8	6	10.2	10	16.0	16	10.6	11	9.9	10	18.6	19	22.6	23		
UK, England/Wales	88.9	100	10.1	13	7.9	10	5.5	7	8.8	11	5.7	7	14.5	16	5.9	7	5.0	6	13.9	17	17.7	22		
UK, Scotland	101.3	100	14.2	14	9.9	10	4.7	5	9.9	10	7.5	7	17.4	17	4.7	5	10.7	11	15.8	16	23.9	24		

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown

Categories may not add up to total or to 100% because of missing values

\* Data on cause of renal failure from Basque country were not available at the ERA-EDTA Registry

Table A.2.5

**Incident rates per million population, adjusted***at day 1, by cause of renal failure, adjusted for age and gender*

	Cause of renal failure										
	Total	GN	PN	PKD	DM			HT	RVD	Misc	Unkn
					Type I	Type II	Both				
Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	
Austria	137.9	19.6	6.7	5.7	5.6	37.8	43.4	10.7	15.4	18.8	17.3
Belgium, Dutch-speaking	155.4	17.1	8.2	6.1	13.7	22.1	35.8	12.9	22.7	32.4	19.8
Belgium, French-speaking	173.7	21.0	14.2	8.1	5.3	29.3	34.6	23.4	14.6	44.5	13.0
Denmark	142.0	15.7	10.8	8.4	15.2	16.1	31.3	14.3	1.4	33.7	26.4
Finland	87.2	11.4	6.5	8.2	11.2	16.8	28.0	3.9	0.4	17.9	10.7
Greece	153.8	20.7	11.1	7.7	15.1	25.5	40.6	17.3	3.5	13.8	39.0
Iceland	91.7	6.9	3.2		17.3		17.3	35.7		25.4	3.2
Norway	95.8	18.5	9.3	6.7	7.8	6.4	14.2	22.0	1.5	20.6	3.1
Spain, Basque country *	111.3										
Spain, Catalonia	137.6	20.9	14.8	10.9	5.2	22.3	27.5	14.0	11.8	13.6	24.0
Spain, Valencia	138.5	18.0	14.7	9.1			20.1	24.1	4.9	13.9	33.7
Sweden	119.6	18.2	4.9	6.3	13.1	17.7	30.7	11.1	11.5	24.5	12.1
The Netherlands	107.9	10.5	6.2	6.5	6.0	10.9	16.8	11.8	11.8	19.7	24.4
UK, England/Wales	91.2	10.5	8.2	5.5	9.0	5.8	14.8	6.1	5.2	14.2	17.9
UK, Scotland	101.7	14.5	10.0	4.4	9.9	7.5	17.4	4.8	10.5	15.7	24.2

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown

Categories may not add up to total or to 100% because of missing values

\* Data on cause of renal failure from Basque country were not available at the ERA-EDTA Registry

Table A.3.1  
**Incident counts and percentage**  
*at day 90, by age and gender*

	All						0-19						20-44						45-64						65-74						75+					
	Men		Women		All		Men		Women		All		Men		Women		All		Men		Women		All		Men		Women		All							
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%						
Austria	592	100	372	100	964	100	11	2	4	1	15	2	79	13	38	10	117	12	262	44	134	36	396	41	160	27	104	28	264	27	80	14	92	25	172	18
Belgium, Dutch-speaking	511	100	358	100	869	100	1	0	3	1	4	0	53	10	30	8	83	10	141	28	106	30	247	28	167	33	114	32	281	32	149	29	105	29	254	29
Belgium, French-speaking	354	100	305	100	659	100	6	2	3	1	9	1	39	11	34	11	73	11	109	31	94	31	203	31	102	29	91	30	193	29	98	28	82	27	180	27
Denmark	447	100	236	100	683	100	10	2	2	1	12	2	46	10	33	14	79	12	176	39	81	34	257	38	128	29	66	28	194	28	87	19	54	23	141	21
Finland	253	100	182	100	435	100	9	4	7	4	16	4	44	17	26	14	70	16	111	44	69	38	180	41	58	23	53	29	111	26	31	12	27	15	58	13
Greece	1031	100	640	100	1671	100	10	1	3	0	13	1	124	12	60	9	184	11	304	29	168	26	472	28	360	35	234	37	594	36	218	21	164	26	382	23
Iceland	12	100	10	100	22	100							4	33	2	20	6	27		5	50	5	23	6	50	1	10	7	32	2	17	2	20	4	18	
Norway	249	100	141	100	390	100	6	2	1	1	7	2	47	19	28	20	75	19	84	34	47	33	131	34	64	26	28	20	92	24	48	19	37	26	85	22
Spain, Basque country	159	100	78	100	237	100	2	1	3	4	5	2	21	13	10	13	31	13	56	35	27	35	83	35	49	31	25	32	74	31	31	19	13	17	44	19
Spain, Catalonia	560	100	307	100	867	100	7	1	5	2	12	1	69	12	42	14	111	13	161	29	74	24	235	27	172	31	81	26	253	29	151	27	105	34	256	30
Spain, Valencia	360	100	212	100	572	100	10	3	4	2	14	2	51	14	19	9	70	12	119	33	67	32	186	33	109	30	60	28	169	30	71	20	62	29	133	23
Sweden	634	100	341	100	975	100	6	1	9	3	15	2	85	13	57	17	142	15	205	32	111	33	316	32	164	26	81	24	245	25	174	27	83	24	257	26
The Netherlands	907	100	580	100	1487	100	25	3	14	2	39	3	155	17	103	18	258	17	333	37	221	38	554	37	232	26	147	25	379	25	162	18	95	16	257	17
UK, England/Wales	1930	100	1137	100	3069	100	51	3	30	3	81	3	341	18	251	22	592	19	680	35	373	33	1053	34	491	25	286	25	778	25	367	19	197	17	565	18
UK, Scotland	265	100	195	100	460	100	12	5	5	3	17	4	43	16	31	16	74	16	82	31	47	24	129	28	73	28	62	32	135	29	55	21	50	26	105	23

*Percentages are row percentages  
Categories may not add up to total or to 100% because of missing values*



Table A.3.2

**Gender, mean and median age of incident patients***at day 90*

	<b>All</b>				<b>Men</b>				<b>Women</b>			
	<b>%</b>	<b>Mean (Years)</b>	<b>(SD)</b>	<b>Median (years)</b>	<b>%</b>	<b>Mean (Years)</b>	<b>(SD)</b>	<b>Median (years)</b>	<b>%</b>	<b>Mean (Years)</b>	<b>(SD)</b>	<b>Median (years)</b>
Austria	100	61	(15.1)	63.1	61	59.6	(15.3)	61.2	39	63.6	(14.5)	66.2
Belgium, Dutch-speaking	100	66	(14.5)	69.2	59	65.6	(14.2)	69.0	41	66.2	(14.9)	69.8
Belgium, French-speaking	100	64	(16.1)	67.8	54	63.7	(16.4)	67.6	46	64.2	(15.8)	68.0
Denmark	100	62	(15.5)	64.7	65	61.8	(15.5)	64.4	35	62.0	(15.5)	65.3
Finland	100	57	(17.0)	60.8	58	56.7	(16.7)	59.7	42	57.8	(17.4)	62.9
Greece	100	64	(14.9)	68.0	62	63.3	(15.2)	67.0	38	65.4	(14.4)	69.0
Iceland	100	58	(18.4)	65.0	55	56.8	(21.5)	67.4	45	59.2	(14.9)	58.6
Norway	100	60	(17.3)	62.0	64	59.6	(17.4)	62.3	36	59.9	(17.3)	61.0
Spain, Basque country	100	61	(15.9)	65.0	67	61.7	(15.1)	65.6	33	59.9	(17.3)	64.4
Spain, Catalonia	100	64	(16.0)	68.0	65	63.4	(15.6)	67.4	35	64.7	(16.7)	69.1
Spain, Valencia	100	62	(16.4)	66.3	63	61.0	(16.9)	65.2	37	64.6	(15.3)	67.4
Sweden	100	62	(16.5)	65.6	65	63.2	(16.0)	66.2	35	60.6	(17.4)	64.4
The Netherlands	100	59	(16.7)	61.7	61	59.0	(16.8)	61.9	39	58.5	(16.5)	60.9
UK, England/Wales	100	59	(17.5)	62.0	63	59.3	(17.3)	62.8	37	57.7	(17.8)	61.2
UK, Scotland	100	61	(17.9)	65.6	58	59.7	(18.3)	64.3	42	61.8	(17.5)	67.1

Table A.3.3  
**Incident rates per million population, unadjusted**  
*at day 90, by age and gender*

	All			0-19			20-44			45-64			65-74			75+		
	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All
	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp
Austria	151.5	89.5	119.5	11.7	4.4	8.1	51.6	25.4	38.7	272.8	135.3	203.0	544.6	283.0	399.2	445.8	227.8	294.8
Belgium, Dutch-speaking	174.1	118.6	146.0	1.4	4.5	2.9	49.2	28.7	39.1	191.8	146.0	169.0	622.7	365.4	484.3	942.6	388.0	592.5
Belgium, French-speaking	169.9	136.9	152.9	11.2	5.8	8.5	50.5	44.5	47.5	221.8	184.5	202.8	592.9	413.3	492.1	900.4	373.0	547.7
Denmark	168.9	87.2	127.5	15.3	3.2	9.4	47.8	35.4	41.7	252.4	117.1	185.0	662.8	298.2	468.1	623.0	225.3	371.7
Finland	99.7	68.5	83.7	14.0	11.3	12.7	50.0	30.7	40.5	156.9	97.0	126.8	298.5	217.8	253.6	279.0	113.2	165.9
Greece	189.8	115.7	152.4	8.0	2.6	5.4	59.1	29.7	44.7	240.0	127.9	182.9	669.2	374.0	510.5	760.5	387.8	538.3
Iceland	83.7	69.9	76.8				74.3	37.9	56.3		170.1	83.8	685.8	104.3	381.8	320.9	228.3	266.8
Norway	109.1	62.9	86.2	10.5	1.7	6.0	59.9	34.4	46.9	158.1	86.5	121.9	370.5	185.6	284.3	216.6	283.2	241.3
Spain, Basque country	157.6	73.6	114.6	10.9	17.2	14.0	50.2	24.4	37.4	220.9	102.8	160.8	489.5	214.9	341.9	583.5	134.5	293.7
Spain, Catalonia	184.1	96.6	139.4	11.3	8.5	9.9	56.0	35.1	45.7	221.3	98.0	158.5	609.6	240.0	408.3	850.1	345.3	531.4
Spain, Valencia	174.7	99.0	136.1	22.4	9.5	16.2	59.8	22.9	41.6	257.2	138.3	196.4	598.2	271.8	419.4	623.0	330.1	440.7
Sweden	143.8	75.8	109.4	5.5	8.6	7.0	56.5	39.4	48.1	177.7	97.9	138.1	474.3	206.2	331.7	567.7	170.5	323.9
The Netherlands	114.7	71.8	93.0	12.5	7.3	10.0	51.2	35.1	43.3	167.2	113.3	140.5	418.4	226.9	315.2	478.1	150.0	264.4
UK, England/Wales	110.4	61.7	85.5	11.1	6.8	9.0	54.8	39.3	46.9	160.8	86.3	123.1	348.0	178.5	258.2	367.0	114.4	207.5
UK, Scotland	108.9	74.2	90.9	19.2	8.4	13.9	49.2	33.7	41.2	135.2	74.4	104.2	364.9	252.1	302.7	439.0	214.1	292.6

Table A.3.4  
**Incident rates per million population, unadjusted**  
*at day 90, by cause of renal failure*

	Cause of renal failure																					
	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn	
									Type I		Type II		Both									
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%
Austria	119.5	100	18.0	15	6.1	5	5.5	5	5.7	5	33.2	28	38.9	33	8.7	7	11.5	10	15.9	13	14.9	12
Belgium, Dutch-speaking	146.0	100	17.5	12	8.4	6	6.4	4	13.8	9	20.8	14	34.6	24	12.6	9	19.5	13	29.7	20	17.1	12
Belgium, French-speaking	152.9	100	20.2	13	13.0	9	7.7	5	4.4	3	27.8	18	32.2	21	21.1	14	10.7	7	37.6	25	10.0	7
Denmark	127.5	100	14.9	12	9.5	7	7.8	6	14.8	12	14.0	11	28.8	23	13.4	11	1.3	1	28.2	22	23.5	18
Finland	83.7	100	11.5	14	6.7	8	8.9	11	11.5	14	16.2	19	27.7	33	3.5	4	0.2	0	15.8	19	9.4	11
Greece	152.4	100	20.8	14	10.6	7	8.0	5	15.5	10	26.5	17	42.0	28	17.4	11	3.5	2	13.0	9	37.1	24
Iceland	76.8	100	7.0	9	3.5	5			14.0	18			14.0	18	27.9	36			20.9	27	3.5	5
Norway	86.2	100	17.5	20	8.8	10	6.6	8	7.3	8	4.9	6	12.2	14	20.6	24	1.1	1	16.8	19	2.7	3
Spain, Basque country *	114.6	100																				
Spain, Catalonia	139.4	100	21.2	15	15.0	11	11.3	8	5.3	4	22.3	16	27.7	20	14.6	11	11.1	8	14.5	10	24.0	17
Spain, Valencia	136.1	100	18.1	13	14.5	11	9.0	7					19.7	15	23.6	17	4.5	3	14.3	10	32.4	24
Sweden	109.4	100	17.2	16	4.6	4	6.4	6	12.0	11	16.5	15	28.5	26	10.7	10	10.6	10	21.1	19	10.3	9
The Netherlands	93.0	100	9.8	11	5.6	6	6.5	7	5.7	6	10.0	11	15.7	17	10.1	11	8.3	9	16.0	17	21.0	23
UK, England/Wales	85.5	100	10.1	13	7.5	10	5.8	8	8.4	11	5.5	7	14.0	16	5.7	7	4.1	5	13.0	17	17.0	22
UK, Scotland	90.9	100	14.0	15	9.3	10	4.7	5	9.1	10	6.3	7	15.4	17	4.5	5	8.5	9	13.6	15	20.7	23

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown  
 Categories may not add up to total or to 100% because of missing values  
 \* Data on cause of renal failure from Basque country were not available at the ERA-EDTA Registry

Table A.3.5

**Incident rates per million population, adjusted***at day 90, by cause of renal failure, adjusted for age and gender*

	Cause of renal failure										
	Total	GN	PN	PKD	DM			HT	RVD	Misc	Unkn
					Type I	Type II	Both				
Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	
Austria	120.6	18.4	5.7	5.4	5.4	33.2	38.6	9.3	12.5	15.5	15.1
Belgium, Dutch-speaking	141.5	16.8	7.8	6.1	12.7	20.2	32.9	12.4	19.6	28.3	17.2
Belgium, French-speaking	155.8	20.5	13.2	7.6	4.3	27.2	31.5	21.7	12.2	37.8	10.8
Denmark	130.9	15.2	10.2	7.5	14.1	14.9	29.1	13.3	1.4	29.6	24.7
Finland	82.7	11.2	6.5	8.2	11.0	15.6	26.6	3.7	0.2	16.0	10.2
Greece	143.4	20.0	10.3	7.6	14.2	24.7	39.0	16.3	3.3	12.2	34.8
Iceland	91.7	6.9	3.2		17.3		17.3	35.7		25.4	3.2
Norway	87.7	18.2	8.7	6.7	7.5	5.2	12.6	20.3	1.0	17.6	2.6
Spain, Basque country *	107.9										
Spain, Catalonia	131.3	20.4	14.1	10.6	5.0	20.8	25.8	13.5	10.8	13.4	22.6
Spain, Valencia	135.1	17.8	14.1	9.1			19.7	23.7	4.6	13.7	32.3
Sweden	105.6	17.2	4.4	6.0	12.0	16.2	28.2	10.0	10.0	19.9	9.8
The Netherlands	99.8	10.3	5.8	6.5	5.9	10.6	16.5	11.2	9.8	17.0	22.7
UK, England/Wales	87.4	10.4	7.7	5.8	8.6	5.6	14.2	5.8	4.3	13.2	17.2
UK, Scotland	91.8	14.5	9.5	4.4	9.1	6.4	15.5	4.6	8.3	13.8	21.1

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown  
 Categories may not add up to total or to 100% because of missing values

\* Data on cause of renal failure from Basque country were not available at the ERA-EDTA Registry

Table A.3.6  
Incident counts

at day 90, by established therapy

	Total	Haemodialysis						Peritoneal dialysis				Transplant			Unknown	Missing	
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver	Tx, type unknown			Total Tx
Austria	964	764	0	2	2	64	832	17	82		99	23	10		33		
Belgium, Dutch-speaking	869	542	0	81	1	118	742	67	50	2	119	0	7	1	8		
Belgium, French-speaking	659	563	4	20	2	4	593	23	35	1	59	2	5	0	7	0	
Denmark	683	435	0				435	86	143		229	8	9	2	19		
Finland	435	313	8				323	31	78		109	1	2	0	3		
Greece	1671	1447	0		12	7	1466	15	180	0	195	9	1		10		
Iceland	22	14	0				14			6	6	2	0		2		
Norway	390	286					286			52	52	26	24		50		2
Spain, Basque country	237	153	0	0			153		79		79		2		2	3	
Spain, Catalonia	867	775	0				775	46	38		84	2	6		8		0
Spain, Valencia	572	510	0				510		58		58			4	4		
Sweden	975	609	4				613	26	246	40	312	43	6		49		1
The Netherlands	1487	901	0				901	63	458	2	523	41	22	0	63		
UK, England/Wales	3069	1849	1	1	8		1859		967	75	1042	14	133	18	165		0
UK, Scotland	460	326	0				326	29	84	0	113	8	9	3	20		1

" " is unavailable

Table A.3.7  
**Incident rates per million population, unadjusted**  
*at day 90, by established therapy*

	Total	Haemodialysis						Peritoneal dialysis				Transplant			Unknown	Missing	
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver	Tx, type unknown			Total Tx
		Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp			Pmp
Austria	119.5	94.7	0.0	0.2	0.2	7.9	103.2	2.1	10.2		12.3	2.9	1.2		4.1		
Belgium, Dutch-speaking	146.0	91.1	0.0	13.6	0.2	19.8	124.7	11.3	8.4	0.3	20.0	0.0	1.2	0.2	1.3		
Belgium, French-speaking	152.9	130.6	0.9	4.6	0.5	0.9	137.6	5.3	8.1	0.2	13.7	0.5	1.2	0.0	1.6	0.0	
Denmark	127.5	81.2	0.0				81.2	16.1	26.7		42.8	1.5	1.7	0.4	3.5		
Finland	83.7	60.3	1.5			0.4	62.2	6.0	15.0		21.0	0.2	0.4	0.0	0.6		
Greece	152.4	132.0	0.0		1.1	0.6	133.7	1.4	16.4	0.0	17.8	0.8	0.1		0.9		
Iceland	76.8	48.9	0.0				48.9			20.9	20.9	7.0	0.0		7.0		
Norway	86.2	63.2					63.2			11.5	11.5	5.7	5.3		11.1		0.4
Spain, Basque country	114.6	74.0	0.0	0.0			74.0		38.2		38.2		1.0		1.0	1.5	
Spain, Catalonia	139.4	124.6	0.0				124.6	7.4	6.1		13.5	0.3	1.0		1.3		0.0
Spain, Valencia	136.1	121.4	0.0				121.4		13.8		13.8			1.0	1.0		
Sweden	109.4	68.4	0.4				68.8	2.9	27.6	4.5	35.0	4.8	0.7		5.5		0.1
The Netherlands	93.0	56.4	0.0				56.4	3.9	28.6	0.1	32.7	2.6	1.4	0.0	3.9		
UK, England/Wales	85.5	51.5	0.0	0.0	0.2		51.8		26.9	2.1	29.0	0.4	3.7	0.5	4.6		0.0
UK, Scotland	90.9	64.4	0.0				64.4	5.7	16.6	0.0	22.3	1.6	1.8	0.6	4.0		0.2

" " is unavailable

Table A.3.8

**Incident rates per million population, adjusted***at day 90, by established therapy, adjusted for age and gender*

	Total	Haemodialysis						Peritoneal dialysis				Transplant				Unknown	Missing
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver	Tx, type unknown	Total Tx		
Austria	120.6	96.0	0.0	0.2	0.3	7.8	104.3	2.1	10.2		12.3	3.0	1.1		4.1		
Belgium, Dutch-speaking	141.5	87.8	0.0	13.2	0.3	19.3	120.6	11.2	8.1	0.4	19.6	0.0	1.1	0.2	1.3		
Belgium, French-speaking	155.8	133.2	1.0	4.3	0.4	0.9	139.8	5.5	8.6	0.2	14.3	0.5	1.2	0.0	1.7	0.0	
Denmark	130.9	84.6	0.0				84.6	16.3	26.5		42.9	1.5	1.7	0.3	3.5		
Finland	82.7	59.9	1.4				61.8	6.0	14.4		20.4	0.2	0.4	0.0	0.6		
Greece	143.4	124.6	0.0		1.0	0.6	126.2	1.1	15.3	0.0	16.4	0.8	0.1		0.9		
Iceland	91.7	58.8	0.0				58.8			26.2	26.2	6.7			6.7		
Norway	87.7	64.2					64.2			11.9	11.9	6.0	5.2		11.3		0.4
Spain, Basque country	107.9	69.5	0.0	0.0			69.5		36.0		36.0		1.2		1.2	1.3	
Spain, Catalonia	131.3	116.8	0.0				116.8	7.3	5.9		13.1	0.3	1.1		1.4		0.0
Spain, Valencia	135.1	120.7	0.0				120.7		13.4		13.4			1.1	1.1		
Sweden	105.6	65.4	0.4				65.8	3.0	26.6	4.4	34.0	4.9	0.7		5.7		0.1
The Netherlands	99.8	61.9	0.0				61.9	4.0	29.9	0.1	34.1	2.6	1.3	0.0	3.8		
UK, England/Wales	87.4	52.6	0.0	0.0	0.2		52.8		27.6	2.1	29.8	0.4	3.8	0.5	4.7		0.0
UK, Scotland	91.8	65.2	0.0				65.2	5.8	16.6	0.0	22.4	1.6	1.8	0.6	4.0		0.2

*" " is unavailable*

Table A.3.9  
**Percentage of established therapy, unadjusted**  
*at day 90*

	Total	Haemodialysis						Peritoneal dialysis				Transplant			Unknown	Missing	
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver	Tx, type unknown			Total Tx
		%	%	%	%	%	%	%	%	%	%	%	%	%			%
Austria	100	79	0	0	0	7	86	2	9		10	2	1		3		
Belgium, Dutch-speaking	100	62	0	9	0	14	85	8	6	0	14	0	1	0	1		
Belgium, French-speaking	100	85	1	3	0	1	90	3	5	0	9	0	1	0	1	0	
Denmark	100	64	0				64	13	21		34	1	1	0	3		
Finland	100	72	2				74	7	18		25	0	0	0	1		
Greece	100	87	0		1	0	88	1	11	0	12	1	0		1		
Iceland	100	64	0				64			27	27	9	0		9		
Norway	100	73					73			13	13	7	6		13		1
Spain, Basque country	100	65	0	0			65		33		33		1		1	1	
Spain, Catalonia	100	89	0				89	5	4		10	0	1		1		0
Spain, Valencia	100	89	0				89		10		10			1	1		
Sweden	100	62	0				63	3	25	4	32	4	1		5		0
The Netherlands	100	61	0				61	4	31	0	35	3	1	0	4		
UK, England/Wales	100	60	0	0	0		61		32	2	34	0	4	1	5		0
UK, Scotland	100	71	0				71	6	18	0	25	2	2	1	4		0

*Categories may not add up to total or to 100% because of missing values  
 " " is unavailable*



Table A.3.10

**Percentage of established therapy, unadjusted***at day 90, by age, gender and primary diagnosis*

	Total				0-19				20-44				45-64				65-74				75+				Male				Female				DM				Non DM			
	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth
	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%
Austria	79	10	3	7	27	47	27	0	53	21	18	9	77	11	2	10	88	7	0	5	97	2	0	1	77	11	4	8	83	9	2	6	84	7	1	8	77	12	4	6
Belgium, Dutch-speaking	72	14	1	14	0	75	25	0	53	33	4	11	63	19	2	16	74	10	0	16	85	5	0	10	71	12	1	16	72	16	1	11	76	12	1	11	70	14	1	14
Belgium, French-speaking	89	9	1	1	67	11	22	0	75	22	3	0	85	12	1	1	93	6	0	1	96	4	0	1	90	8	1	1	89	10	2	0	89	9	1	1	89	9	1	1
Denmark	64	34	3		50	33	17		37	49	14		58	40	2		72	28	1		80	20	0		64	33	3		64	34	3		68	30	3		63	35	3	
Finland	74	25	1	0	25	75	0	0	70	27	3	0	71	29	1	0	84	15	0	1	83	16	0	2	74	24	1	1	73	26	1	0	73	26	1	1	74	25	1	0
Greece	88	15	1	1	69	15	8	8	84	14	3	0	88	11	1	1	88	11	0	2	87	12	0	2	87	11	1	1	86	12	1	1	85	13	0	1	87	11	1	1
Iceland	64	27	9	0					83	0	17	0	40	40	20	0	86	14	0	0	25	75	0	0	67	25	8	0	60	30	10	0	100	0	0	0	56	33	11	0
Norway	73	13	13	1	14	14	71	0	67	16	17	0	68	15	17	1	83	9	9	0	82	14	2	1	73	12	14	1	74	15	11	0	64	13	24	0	75	13	11	1
Spain, Basque country	65	33	1	1	0	80	20	0	55	42	3	0	65	34	0	1	65	32	0	3	77	23	0	0	66	33	1	1	62	35	1	3					65	33	1	1
Spain, Catalonia	89	10	1	0	33	42	25	0	77	19	4	0	87	13	0	0	92	8	0	0	97	3	0	0	89	11	0	0	90	8	2	0	89	11	0	0	89	9	1	0
Spain, Valencia	89	10	1		50	29	21		61	37	1		90	10	0		96	4	0		98	2	0		88	11	1		91	9	0		89	11	0		89	10	1	
Sweden	63	32	5	0	27	53	20	0	48	32	20	0	58	37	5	0	67	32	1	0	76	24	0	0	61	34	4	0	66	28	6	0	58	39	3	0	65	30	6	0
The Netherlands	61	35	4		33	59	8		43	46	11		53	41	5		71	28	1		82	18	0		59	37	4		62	33	5		67	32	1		59	36	5	
UK, England/Wales	60	34	5	0	30	44	26	0	41	45	14	0	58	36	5	0	68	31	1	0	78	21	0	1	60	35	5	0	62	32	6	0	56	40	4	0	61	33	6	0
UK, Scotland	71	25	4	0	35	35	29	0	49	36	15	0	71	26	3	0	78	22	0	0	83	16	0	1	70	25	5	0	72	24	4	1	74	18	8	0	70	26	4	0

*Categories may not add up to total or to 100% because of missing values  
 " " is unavailable*

Table A.4.1

**Prevalence counts and percentage***prevalent patients on December 31, by age and gender*

	All						0-19						20-44						45-64						65-74						75+					
	Men		Women		All		Men		Women		All		Men		Women		All		Men		Women		All		Men		Women		All							
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%						
Austria	3668	100	2385	100	6053	100	40	1	41	2	81	1	885	24	549	23	1434	24	1680	46	961	40	2641	44	739	20	470	20	1209	20	324	9	364	15	688	11
Belgium, Dutch-speaking	2807	100	2280	100	5088	100	17	1	17	1	34	1	470	17	327	14	797	16	1132	40	805	35	1937	38	689	25	637	28	1327	26	499	18	494	22	993	20
Belgium, French-speaking	1929	100	1530	100	3459	100	23	1	14	1	37	1	385	20	274	18	659	19	755	39	597	39	1352	39	442	23	366	24	808	23	324	17	277	18	601	17
Denmark	2268	100	1368	100	3636	100	48	2	27	2	75	2	597	26	380	28	977	27	977	43	545	40	1522	42	402	18	255	19	657	18	244	11	161	12	405	11
Finland	1868	100	1299	100	3167	100	78	4	41	3	119	4	414	22	313	24	727	23	914	49	557	43	1471	46	340	18	277	21	617	19	122	7	111	9	233	7
Greece	5471	100	3431	100	8902	100	70	1	47	1	117	1	1016	19	543	16	1559	18	1991	36	1221	36	3212	36	1503	27	1032	30	2535	28	863	16	565	16	1428	16
Iceland	67	100	49	100	116	100	5	7	5	10	10	9	16	24	19	39	35	30	26	39	16	33	42	36	12	18	5	10	17	15	8	12	4	8	12	10
Norway	1748	100	992	100	2740	100	40	2	18	2	58	2	417	24	283	29	700	26	749	43	412	42	1161	42	325	19	176	18	501	18	217	12	103	10	320	12
Spain, Basque country	1144	100	705	100	1849	100	18	2	17	2	35	2	239	21	167	24	406	22	484	42	285	40	769	42	271	24	168	24	439	24	132	12	68	10	200	11
Spain, Catalonia	3905	100	2453	100	6358	100	33	1	23	1	56	1	792	20	455	19	1247	20	1532	39	910	37	2442	38	941	24	607	25	1548	24	607	16	458	19	1065	17
Spain, Valencia	2533	100	1717	100	4250	100	41	2	21	1	62	1	492	19	311	18	803	19	1019	40	653	38	1672	39	580	23	419	24	999	24	401	16	313	18	714	17
Sweden	4144	100	2407	100	6551	100	75	2	59	2	134	2	871	21	546	23	1417	22	1838	44	1034	43	2872	44	754	18	454	19	1208	18	606	15	314	13	920	14
The Netherlands	5978	100	4246	100	10224	100	161	3	120	3	281	3	1566	26	1007	24	2573	25	2653	44	1873	44	4526	44	1059	18	846	20	1905	19	539	9	400	9	939	9
UK, England/Wales	11222	100	7177	100	18402	100	61	1	44	1	105	1	3146	28	2163	30	5309	29	4542	40	2870	40	7412	40	2154	19	1356	19	3511	19	1319	12	744	10	2065	11
UK, Scotland	1918	100	1371	100	3289	100	63	3	30	2	93	3	552	29	456	33	1008	31	780	41	476	35	1256	38	338	18	276	20	614	19	185	10	133	10	318	10

*Percentages are row percentages*

Table A.4.2  
**Gender, mean and median age**  
*prevalent patients on December 31*

	All				Men				Women			
	%	Mean (years)	(SD)	Median (years)	%	Mean (years)	(SD)	Median (years)	%	Mean (years)	(SD)	Median (years)
Austria	100	56	(15.5)	57.9	61	55.7	(15.0)	57.3	39	57.0	(16.3)	58.8
Belgium, Dutch-speaking	100	61	(15.3)	63.2	55	60.1	(15.2)	61.9	45	62.2	(15.5)	64.9
Belgium, French-speaking	100	59	(16.1)	60.5	56	58.6	(16.4)	59.9	44	59.6	(15.9)	61.0
Denmark	100	55	(16.3)	55.5	62	54.5	(16.3)	55.8	38	54.6	(16.4)	55.1
Finland	100	54	(16.0)	54.7	59	53.4	(15.8)	54.4	41	54.3	(16.2)	55.3
Greece	100	60	(15.9)	62.9	61	59.3	(15.9)	62.5	39	60.5	(15.8)	63.8
Iceland	100	50	(19.1)	53.9	58	52.7	(19.0)	55.8	42	46.9	(18.9)	46.6
Norway	100	55	(16.3)	55.4	64	55.4	(16.2)	56.0	36	53.6	(16.5)	54.5
Spain, Basque country	100	56	(15.8)	57.6	62	56.9	(15.7)	57.9	38	55.5	(16.0)	57.2
Spain, Basque country *												
Spain, Catalonia	100	59	(16.0)	60.5	61	58.3	(15.9)	59.5	39	59.7	(16.1)	61.7
Spain, Valencia	100	59	(16.2)	61.1	60	58.3	(16.2)	60.5	40	59.6	(16.1)	61.9
Sweden	100	57	(16.3)	57.2	63	56.9	(16.1)	57.6	37	55.8	(16.5)	56.7
The Netherlands	100	54	(16.2)	55.3	58	53.8	(16.2)	54.8	42	54.6	(16.2)	56.2
UK, England/Wales	100	55	(16.0)	55.5	61	55.3	(16.0)	55.9	39	54.3	(16.0)	55.0
UK, Scotland	100	53	(16.7)	53.8	58	53.0	(16.7)	53.5	42	53.2	(16.9)	54.3

Table A.4.3

**Prevalence per million population, unadjusted***prevalent patients on December 31, by age and gender*

	All			0-19			20-44			45-64			65-74			75+		
	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All
	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp
Austria	938.8	573.6	750.5	42.4	45.6	43.9	578.4	366.7	473.7	1749.5	970.4	1354.0	2515.6	1278.7	1828.2	1805.5	901.1	1179.3
Belgium, Dutch-speaking	956.4	755.6	854.8	24.5	25.6	25.0	436.0	313.1	375.5	1539.5	1108.5	1325.4	2569.1	2041.5	2287.1	3156.6	1825.7	2316.5
Belgium, French-speaking	926.0	686.8	802.4	42.8	27.2	35.1	498.2	358.8	428.9	1536.3	1171.8	1350.8	2569.3	1662.4	2060.2	2976.9	1260.2	1828.7
Denmark	856.7	505.2	679.0	73.2	43.3	58.6	621.0	408.0	516.2	1400.8	787.8	1095.5	2081.6	1152.3	1585.4	1747.4	671.6	1067.6
Finland	736.1	488.8	609.6	121.1	66.5	94.4	470.1	369.6	420.8	1291.8	782.6	1036.5	1749.7	1138.2	1409.7	1098.0	465.3	666.3
Greece	1007.2	620.2	811.9	56.3	40.8	48.8	484.3	269.2	378.9	1571.8	929.3	1244.7	2793.8	1649.5	2178.5	3010.5	1335.9	2012.4
Iceland	467.1	342.4	404.8	112.7	117.4	115.0	297.3	359.9	328.3	858.2	544.4	703.7	1371.6	521.6	927.2	1283.5	456.5	800.3
Norway	766.0	442.5	605.6	70.0	29.9	49.4	531.2	347.6	437.8	1409.8	758.2	1080.3	1881.7	1166.6	1548.3	979.4	788.3	908.5
Spain, Basque country	1133.9	665.4	893.9	98.1	97.5	97.8	570.9	407.8	490.2	1909.1	1085.5	1490.1	2707.1	1443.9	2028.1	2484.7	703.4	1335.1
Spain, Catalonia	1283.7	772.0	1022.3	53.1	39.3	46.4	642.4	380.8	513.6	2105.6	1205.0	1646.9	3334.9	1798.8	2498.3	3417.1	1506.0	2210.7
Spain, Valencia	1229.1	801.6	1011.3	91.9	50.0	71.6	576.8	374.0	476.7	2202.5	1347.6	1765.1	3183.0	1898.1	2479.1	3518.6	1666.3	2365.8
Sweden	940.0	534.8	735.3	68.3	56.7	62.6	579.1	377.6	480.3	1593.3	911.7	1255.4	2180.5	1155.5	1635.3	1977.1	645.0	1159.6
The Netherlands	755.8	525.7	639.5	80.5	62.9	71.9	517.6	342.9	431.5	1332.3	960.1	1148.1	1909.7	1305.9	1584.4	1590.8	631.6	965.9
UK, England/Wales	642.1	389.4	512.5	13.2	10.0	11.7	505.2	338.3	420.7	1073.8	664.1	866.7	1526.5	846.4	1165.2	1319.1	431.9	758.5
UK, Scotland	788.5	521.4	649.7	100.7	50.1	76.0	631.1	495.7	561.7	1286.0	753.4	1014.3	1689.5	1122.1	1376.6	1476.5	569.4	886.1

Table A.4.4  
**Prevalence per million population and percentage, unadjusted**  
*prevalent patients on December 31, by cause of renal failure*

	Cause of renal failure																							
	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing	
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Type I	Type II	Both	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp
Austria	750.5	100	201.4	27	73.5	10	43.0	6	47.5	6	92.5	12	140.0	19	38.4	5	36.5	5	135.6	18	81.6	11		
Belgium, Dutch-speaking	854.8	100	179.6	21	75.1	9	76.1	9	69.0	8	64.5	8	133.6	16	55.4	6	62.2	7	190.3	22	80.6	9		
Belgium, French-speaking	802.4	100	169.6	21	105.5	13	65.2	8	27.6	3	85.6	11	113.2	14	71.0	9	34.8	4	170.3	21	64.0	8		
Denmark	679.0	100	151.6	22	72.1	11	57.3	8	77.9	11	34.0	5	111.9	16	55.5	8	8.6	1	108.5	16	113.5	17		
Finland	609.6	100	150.3	25	73.0	12	71.4	12	103.4	17	45.4	7	148.8	24	18.9	3	1.7	0	110.7	18	34.8	6		
Greece	811.9	100	195.2	24	68.1	8	63.1	8	40.1	5	79.4	10	119.6	15	58.2	7	18.2	2	65.7	8	223.9	28		
Iceland	404.8	100	90.7	22	55.8	14	24.4	6	41.9	10			41.9	10	76.8	19	3.5	1	87.2	22	24.4	6		
Norway	605.6	100	203.4	34	76.7	13	63.9	11					56.1	9	73.8	12	3.1	1	113.6	19	15.0	2		
Spain, Basque country *	893.9	100																						
Spain, Catalonia	1022.3	100	236.5	23	142.1	14	108.7	11	34.2	3	74.8	7	109.0	11	87.0	9	46.9	5	104.5	10	187.0	18		
Spain, Valencia	1011.3	100	202.5	20	145.6	14	89.2	9					84.2	8	128.0	13	28.1	3	119.7	12	213.9	21		
Sweden	735.3	100	205.6	28	64.2	9	61.7	8	91.7	12	44.6	6	136.3	19	42.8	6	32.1	4	147.8	20	44.6	6		
The Netherlands	639.5	100	137.2	21	79.6	12	53.6	8	30.5	5	26.6	4	57.0	9	53.4	8	27.8	4	113.9	18	117.0	18		
UK, England/Wales	512.5	100	101.2	21	71.6	15	45.9	9	37.0	8	17.1	4	54.1	11	31.2	6	13.3	3	75.3	15	93.1	19		
UK, Scotland	649.7	100	157.8	24	109.4	17	62.2	10	49.4	8	16.6	3	66.0	10	33.2	5	19.0	3	107.1	16	95.0	15		

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown

Categories may not add up to total or to 100% because of missing values

\* Data on cause of renal failure from Basque country were not available at the ERA-EDTA Registry

Table A.4.5

**Prevalence per million population, adjusted***prevalent patients on December 31, by cause of renal failure, adjusted for age and gender*

	Cause of renal failure											
	Total	GN	PN	PKD	DM			HT	RVD	Misc	Unkn	Missing
					Type I	Type II	Both					
Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	
Austria	746.8	198.5	71.9	42.4	45.7	93.1	138.8	39.7	39.0	134.2	81.9	
Belgium, Dutch-speaking	819.4	173.4	72.2	71.9	63.7	61.1	124.9	53.8	62.6	179.8	79.1	
Belgium, French-speaking	818.6	171.8	106.2	67.0	27.2	85.2	112.4	72.9	39.3	172.7	68.0	
Denmark	679.3	149.4	73.6	54.8	74.7	34.7	109.4	56.1	9.3	111.2	115.5	
Finland	590.4	145.8	69.8	67.1	95.1	45.0	140.1	19.7	1.8	109.6	36.6	
Greece	781.7	190.0	66.1	61.1	38.0	74.1	112.1	56.2	17.4	63.3	215.4	
Iceland	458.2	102.1	59.8	27.0	50.1		50.1	102.2	4.2	89.6	23.2	
Norway	621.9	209.7	79.0	67.4			57.7	73.6	2.6	116.8	15.2	
Spain, Basque country *	838.1											
Spain, Catalonia	973.2	227.5	134.2	103.0	33.0	70.4	103.4	82.4	45.8	100.0	176.4	
Spain, Valencia	1003.2	201.0	139.7	89.4			82.9	128.9	29.0	117.6	214.7	
Sweden	713.9	202.5	62.6	58.4	87.7	43.6	131.3	40.6	30.5	145.5	42.2	
The Netherlands	659.4	137.6	79.8	55.1	30.0	28.2	58.2	57.0	32.5	116.8	122.2	
UK, England/Wales	521.8	102.9	73.2	45.8	37.1	17.6	54.7	31.9	13.8	77.2	94.7	
UK, Scotland	649.2	158.1	109.8	60.1	48.4	16.6	65.1	34.0	18.9	107.6	95.6	

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown  
 Categories may not add up to total or to 100% because of missing values

\* Data on cause of renal failure from Basque country were not available at the ERA-EDTA Registry

Table A.4.6  
Prevalence counts

*prevalent patients on December 31, by established therapy*

	Total	Haemodialysis						Peritoneal dialysis				Transplant			Unknown	Missing	
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver	Tx, type unknown			Total Tx
		N	N	N	N	N	N	N	N	N	N	N	N	N			N
Austria	6053	2348	9	2	1	485	2845	66	177		243	237	2726		2963	2	
Belgium, Dutch-speaking	5088	1808	7	299	2	462	2578	159	112	5	276	28	1367	839	2234		
Belgium, French-speaking	3459	1691	25	93	19	52	1880	81	87	8	176	43	706	639	1388	15	
Denmark	3636	1633	14				1647	246	356		602	343	1013	25	1381	6	
Finland	3167	928	24			37	989	83	167		250	184	1721	9	1914		
Greece	8902	6558	1		27	57	6643	119	625	1	745	774	739	1	1514		
Iceland	116	34					34			16	16	50	16		66		
Norway	2740	613	2				615			99	99	982	1039		2021		5
Spain, Basque country	1849	633	5	3			641		277		277		845		845	86	
Spain, Catalonia	6358	3322	1				3323	122	75		197	97	2741		2838		
Spain, Valencia	4250	2504	2				2506		209		209			1535	1535		
Sweden	6551	2269	61				2330	122	546	112	780	1257	2180		3437	3	1
The Netherlands	10224	3334	81				3415	473	1090	5	1568	1084	4145	10	5239	2	
UK, England/Wales	18402	6292	239	1	69		6601		2575	486	3061	528	5875	963	7366	1297	37
UK, Scotland	3289	1224	47				1271	159	252		411	225	1331	49	1605		2

" " is unavailable

Table A.4.7

**Prevalence per million population, unadjusted***prevalent patients on December 31, by established therapy*

	Total	Haemodialysis					Peritoneal dialysis				Transplant			Unknown	Missing		
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver			Tx, type unknown	Total Tx
		Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp			Pmp	Pmp
Austria	750.5	291.1	1.1	0.2	0.1	60.1	352.7	8.2	21.9		30.1	29.4	338.0		367.4	0.2	
Belgium, Dutch-speaking	854.8	303.7	1.2	50.2	0.3	77.6	433.1	26.7	18.8	0.8	46.4	4.7	229.6	140.9	375.3		
Belgium, French-speaking	802.4	392.3	5.8	21.6	4.4	12.1	436.1	18.8	20.2	1.9	40.8	10.0	163.8	148.2	322.0	3.5	
Denmark	679.0	304.9	2.6				307.6	45.9	66.5		112.4	64.1	189.2	4.7	257.9	1.1	
Finland	609.6	178.6	4.6			7.1	190.4	16.0	32.1		48.1	35.4	331.3	1.7	368.4		
Greece	811.9	598.1	0.1		2.5	5.2	605.9	10.9	57.0	0.1	67.9	70.6	67.4	0.1	138.1		
Iceland	404.8	118.6					118.6			55.8	55.8	174.5	55.8		230.3		
Norway	605.6	135.5	0.4				135.9			21.9	21.9	217.1	229.7		446.7		1.1
Spain, Basque country	893.9	306.0	2.4	1.5			309.9		133.9		133.9		408.5		408.5	41.6	
Spain, Catalonia	1022.3	534.1	0.2				534.3	19.6	12.1		31.7	15.6	440.7		456.3		
Spain, Valencia	1011.3	595.8	0.5				596.3		49.7		49.7			365.2	365.2		
Sweden	735.3	254.7	6.8				261.5	13.7	61.3	12.6	87.6	141.1	244.7		385.8	0.3	0.1
The Netherlands	639.5	208.5	5.1				213.6	29.6	68.2	0.3	98.1	67.8	259.3	0.6	327.7	0.1	
UK, England/Wales	512.5	175.2	6.7	0.0	1.9		183.8		71.7	13.5	85.2	14.7	163.6	26.8	205.1	36.1	1.0
UK, Scotland	649.7	241.8	9.3				251.1	31.4	49.8		81.2	44.4	262.9	9.7	317.1		0.4

*" " is unavailable*



Table A.4.8

**Prevalence per million population, adjusted***prevalent patients on December 31, by established therapy, adjusted for age and gender*

	Total	Haemodialysis						Peritoneal dialysis				Transplant				Unknown	Missing
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver	Tx, type unknown	Total Tx		
Austria	746.8	293.5	1.1	0.2	0.2	59.7	354.7	8.2	21.8		30.0	29.6	332.4		362.0	0.2	
Belgium, Dutch-speaking	819.4	290.3	1.2	47.9	0.4	74.4	414.2	26.4	17.7	0.9	45.0	4.9	221.3	134.0	360.2		
Belgium, French-speaking	818.6	399.3	6.0	21.2	4.2	12.9	443.6	19.2	20.2	1.7	41.1	10.4	169.2	150.8	330.4	3.6	
Denmark	679.3	312.1	2.4				314.5	46.2	66.2		112.4	64.1	182.6	4.6	251.3	1.1	
Finland	590.4	178.5	4.6				7.0	15.8	31.0		46.7	33.9	315.7	1.6	351.3		
Greece	781.7	573.0	0.1		2.4	5.0	580.6	10.3	54.5	0.1	64.9	69.9	66.3	0.1	136.3		
Iceland	458.2	149.9					149.9			67.0	67.0	181.2	60.1		241.2		
Norway	621.9	134.9	0.4				136.3			22.0	22.0	224.7	237.8		462.5		1.1
Spain, Basque country	838.1	285.6	2.2	1.8			289.6		130.3		130.3		379.3		379.3	39.0	
Spain, Catalonia	973.2	501.4	0.2				501.6	19.2	11.3		30.5	15.1	426.0		441.1		
Spain, Valencia	1003.2	586.5	0.5				587.0		48.2		48.2			368.0	368.0		
Sweden	713.9	242.0	6.7				248.7	13.7	59.3	12.3	85.3	141.2	238.3		379.5	0.3	0.1
The Netherlands	659.4	226.9	4.8				231.7	30.6	70.5	0.3	101.4	66.6	259.0	0.6	326.2	0.1	
UK, England/Wales	521.8	178.8	6.7	0.0	1.9		187.4		73.2	14.0	87.2	15.1	165.7	27.3	208.1	36.8	1.0
UK, Scotland	649.2	243.8	9.0				252.8	31.1	50.0		81.1	44.7	260.5	9.7	314.9		0.4

*" " is unavailable*

Table A.4.9  
**Percentage of established therapy, unadjusted**  
*prevalent patients on December 31*

	Total	Haemodialysis					Peritoneal dialysis				Transplant			Unknown	Missing		
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver			Tx, type unknown	Total Tx
	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%
Austria	100	39	0	0	0	8	47	1	3		4	4	45		49	0	
Belgium, Dutch-speaking	100	36	0	6	0	9	51	3	2	0	5	1	27	16	44		
Belgium, French-speaking	100	49	1	3	1	2	54	2	3	0	5	1	20	18	40	0	
Denmark	100	45	0				45	7	10		17	9	28	1	38	0	
Finland	100	29	1			1	31	3	5		8	6	54	0	60		
Greece	100	74	0		0	1	75	1	7	0	8	9	8	0	17		
Iceland	100	29					29			14	14	43	14		57		
Norway	100	22	0				22			4	4	36	38		74		0
Spain, Basque country	100	34	0	0			35		15		15		46		46	5	
Spain, Catalonia	100	52	0				52	2	1		3	2	43		45		
Spain, Valencia	100	59	0				59		5		5			36	36		
Sweden	100	35	1				36	2	8	2	12	19	33		52	0	0
The Netherlands	100	33	1				33	5	11	0	15	11	41	0	51	0	
UK, England/Wales	100	34	1	0	0		36		14	3	17	3	32	5	40	7	0
UK, Scotland	100	37	1				39	5	8		12	7	40	1	49		0

*Categories may not add up to total or to 100% because of missing values  
 " " is unavailable*

Table A.4.10

**Percentage of established therapy, unadjusted***prevalent patients on December 31, by age, gender and primary diagnosis*

	Total				0-19				20-44				45-64				65-74				75+				Male				Female				DM				Non DM			
	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth	HD	PD	TX	Oth
	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%
Austria	39	4	49	8	10	15	74	1	21	4	66	8	33	4	54	8	53	3	36	8	77	2	12	9	38	4	49	9	41	4	48	6	56	5	29	10	35	4	53	8
Belgium, Dutch-speaking	42	5	44	9	3	18	71	9	18	8	71	4	28	5	61	6	51	5	32	13	76	4	5	15	39	5	47	9	44	6	41	9	54	5	28	12	39	5	47	9
Belgium, French-speaking	52	6	40	2	16	5	76	3	29	5	64	3	38	5	55	2	69	6	22	3	90	4	3	3	51	5	42	3	54	6	38	2	73	6	18	3	49	5	44	2
Denmark	45	17	38	0	16	11	73	0	29	13	59	0	39	19	42	0	65	20	15	0	82	14	3	0	45	16	39	0	46	18	36	0	50	20	30	0	44	16	40	0
Finland	30	8	60	2	5	14	81	0	19	5	76	1	24	7	67	2	46	10	42	2	74	12	11	3	30	8	61	2	30	8	60	1	35	10	52	3	28	7	63	1
Greece	74	9	18	1	21	15	64	1	51	5	43	1	71	8	20	1	86	10	4	1	89	10	1	1	74	8	18	1	74	9	16	1	83	14	3	1	72	7	19	1
Iceland	29	14	57		0	0	100		14	9	77		26	14	60		65	12	24		58	42	0		31	13	55		27	14	59		67	0	33		25	15	60	
Norway	22	4	74	0	7	2	91	0	12	2	86	0	17	3	80	0	30	4	65	0	57	9	34	0	23	4	73	0	21	4	75	0	31	4	64	0	22	4	75	0
Spain, Basque country	35	15	46	5	0	69	29	3	21	11	61	7	27	12	54	6	44	16	37	3	76	21	3	1	36	16	43	5	32	14	50	5					35	15	46	5
Spain, Catalonia	52	3	45		23	11	66		31	3	66		39	4	57		63	3	34		94	2	4		51	3	46		54	3	43		72	8	20		50	3	48	
Spain, Valencia	59	5	36		10	8	82		33	8	59		44	4	52		82	4	15		96	4	0		58	5	37		60	5	35		80	9	11		57	5	38	
Sweden	36	12	52	0	7	10	83	0	20	8	72	0	27	10	63	0	48	17	35	0	74	16	9	0	35	13	52	0	36	11	54	0	40	18	42	0	34	11	55	0
The Netherlands	33	15	51	0	15	15	70	0	20	16	64	0	26	16	58	0	49	16	35	0	80	12	9	0	33	16	51	0	34	15	51	0	49	20	31	0	32	15	53	0
UK, England/Wales	35	17	40	8	13	11	68	8	21	14	55	10	29	16	46	9	50	21	24	5	72	19	8	2	36	16	40	8	35	17	40	7	45	25	23	7	34	16	42	8
UK, Scotland	39	12	49	0	11	26	63	0	25	9	66	0	34	12	54	0	57	15	27	0	75	16	9	0	38	12	50	0	40	13	47	0	50	18	32	0	37	12	51	0

*Categories may not add up to total or to 100% because of missing values  
 " " is unavailable*

Table A.4.11  
**Patients living on a functioning graft, unadjusted**  
*prevalent patients on December 31*

	Total		Tx, living related donor		Tx, living unrelated donor		Tx, living type unkn		All Tx		Tx, cadaver donor		Tx, type unkn	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Austria	2963	100	186	6	51	2			237	8	2726	92		
Belgium, Dutch-speaking	2234	100	20	1	8	0			28	1	1367	61	839	38
Belgium, French-speaking	1388	100	33	2	10	1			43	3	706	51	639	46
Denmark	1381	100	326	24	17	1			343	25	1013	73	25	2
Finland	1914	100	184	10					184	10	1721	90	9	0
Greece	1514	100	770	51	4	0			774	51	739	49	1	0
Iceland	66	100	48	73	2	3			50	76	16	24		
Norway	2021	100	853	42	129	6			982	49	1039	51		
Spain, Basque country	845	100									845	100		
Spain, Catalonia	2838	100	97	3					97	3	2741	97		
Spain, Valencia	1535	100											1535	100
Sweden	3437	100	1039	30	218	6			1257	37	2180	63		
The Netherlands	5239	100					1084	21	1084	21	4145	79	10	0
UK, England/Wales	7366	100	502	7	22	0	4	0	528	7	5875	80	963	13
UK, Scotland	1605	100	202	13	22	1	1	0	225	14	1331	83	49	3

*Categories may not add up to total or to 100% because of missing values  
 " " is unavailable*

Table A.5.1

**90-day, one-, two- and five-year survival probabilities (cohort 1992-1996): Incident RRT patients, unadjusted***from day 1 to 90 days, one, two and five years, by age, gender and primary diagnosis*

	90 day Survival (95% CI)		1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>								
0-19	99.5	(98.7 - 99.8)	96.9	(95.6 - 97.8)	94.9	(93.3 - 96.1)	92.4	(90.6 - 93.8)
20-44	98.7	(98.4 - 99.0)	95.4	(94.9 - 95.8)	91.5	(90.9 - 92.1)	83.3	(82.6 - 84.1)
45-64	95.9	(95.6 - 96.2)	87.0	(86.5 - 87.5)	76.9	(76.4 - 77.4)	55.2	(54.7 - 55.6)
65-74	92.0	(91.5 - 92.4)	76.2	(75.6 - 76.8)	59.9	(59.4 - 60.5)	28.2	(28.0 - 28.4)
75+	85.8	(85.0 - 86.6)	64.6	(63.7 - 65.4)	46.1	(45.5 - 46.8)	14.9	(14.8 - 15.0)
Male	94.0	(93.7 - 94.2)	82.7	(82.2 - 83.1)	70.8	(70.4 - 71.2)	47.3	(47.0 - 47.6)
Female	93.9	(93.5 - 94.3)	82.2	(81.7 - 82.7)	70.6	(70.1 - 71.1)	47.9	(47.5 - 48.3)
DM	93.7	(93.1 - 94.2)	77.4	(76.6 - 78.1)	59.6	(58.9 - 60.3)	30.2	(29.8 - 30.5)
Non DM	93.9	(93.6 - 94.1)	83.4	(83.1 - 83.8)	73.0	(72.7 - 73.4)	51.3	(51.0 - 51.6)
All	93.9	(93.7 - 94.2)	82.5	(82.2 - 82.8)	70.7	(70.4 - 71.0)	47.5	(47.3 - 47.8)

Table A.5.2

**90-day, one-, two- and five-year survival probabilities (cohort 1992-1996): Incident RRT patients, adjusted***from day 1 to 90 days, one, two and five years, adjusted for age, gender and primary diagnosis*

	90 day Survival (95% CI)		1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>								
0-19	99.2	(98.6 - 99.8)	96.3	(95.0 - 97.6)	94.0	(92.4 - 95.7)	91.5	(89.5 - 93.4)
20-44	98.7	(98.5 - 99.0)	95.4	(94.9 - 95.9)	91.6	(90.9 - 92.3)	83.4	(82.5 - 84.3)
45-64	96.0	(95.7 - 96.3)	87.4	(86.8 - 87.9)	77.5	(76.8 - 78.2)	55.5	(54.6 - 56.3)
65-74	92.1	(91.6 - 92.6)	76.7	(75.9 - 77.4)	60.4	(59.5 - 61.3)	27.9	(27.1 - 28.8)
75+	85.3	(84.3 - 86.3)	63.5	(62.2 - 64.9)	44.7	(43.4 - 46.1)	13.4	(12.5 - 14.4)
Male	95.1	(94.9 - 95.4)	85.6	(85.1 - 86.0)	74.6	(74.0 - 75.1)	48.4	(47.7 - 49.1)
Female	95.4	(95.1 - 95.7)	86.0	(85.5 - 86.5)	75.6	(75.0 - 76.3)	50.9	(50.1 - 51.8)
DM	94.7	(94.3 - 95.2)	80.3	(79.4 - 81.1)	63.1	(62.0 - 64.2)	29.8	(28.7 - 30.9)
Non DM	95.3	(95.0 - 95.5)	86.7	(86.3 - 87.0)	77.3	(76.8 - 77.8)	54.0	(53.4 - 54.6)
All	95.2	(95.1 - 95.4)	85.7	(85.4 - 86.1)	75.0	(74.6 - 75.5)	49.4	(48.8 - 50.0)

Table A.5.3

**One-, two- and five-year survival probabilities (cohort 1992-1996): Incident RRT patients, unadjusted***from day 91 to one, two and five years + 90 days, by age, gender and primary diagnosis*

	<b>1 year Survival (95% CI)</b>	<b>2 year Survival (95% CI)</b>	<b>5 year Survival (95% CI)</b>
<b>ALL COUNTRIES</b>			
0-19	96.5 (95.0 - 97.5)	95.0 (93.4 - 96.3)	92.1 (90.2 - 93.7)
20-44	95.5 (95.0 - 96.0)	91.7 (91.1 - 92.3)	83.2 (82.5 - 84.0)
45-64	87.9 (87.5 - 88.4)	77.9 (77.4 - 78.4)	55.4 (54.9 - 55.9)
65-74	78.3 (77.7 - 78.9)	61.3 (60.7 - 61.9)	28.6 (28.4 - 28.9)
75+	69.3 (68.3 - 70.2)	49.5 (48.7 - 50.2)	15.3 (15.1 - 15.4)
Male	84.4 (84.0 - 84.8)	72.3 (71.9 - 72.7)	48.0 (47.7 - 48.3)
Female	84.2 (83.7 - 84.7)	72.4 (71.9 - 72.9)	48.8 (48.4 - 49.2)
DM	77.1 (76.3 - 77.9)	59.7 (58.9 - 60.4)	29.6 (29.2 - 29.9)
Non DM	85.8 (85.5 - 86.2)	75.1 (74.7 - 75.5)	52.4 (52.1 - 52.7)
All	84.3 (84.0 - 84.6)	72.3 (72.0 - 72.7)	48.3 (48.1 - 48.6)

Table A.5.4

**One-, two- and five-year survival probabilities (cohort 1992-1996): Incident RRT patients, adjusted***from day 91 to one, two and five years + 90 days, adjusted for age, gender and primary diagnosis*

	<b>1 year Survival (95% CI)</b>	<b>2 year Survival (95% CI)</b>	<b>5 year Survival (95% CI)</b>
<b>ALL COUNTRIES</b>			
0-19	95.8 (94.4 - 97.3)	94.1 (92.4 - 95.9)	91.2 (89.1 - 93.3)
20-44	95.6 (95.1 - 96.1)	91.8 (91.1 - 92.5)	83.5 (82.6 - 84.4)
45-64	88.3 (87.8 - 88.9)	78.6 (77.9 - 79.3)	56.1 (55.3 - 57.0)
65-74	78.8 (78.0 - 79.6)	61.8 (60.9 - 62.8)	28.7 (27.8 - 29.6)
75+	68.3 (66.9 - 69.7)	47.9 (46.4 - 49.4)	14.0 (13.0 - 15.1)
Male	86.9 (86.5 - 87.3)	75.6 (75.0 - 76.2)	48.9 (48.2 - 49.6)
Female	87.4 (86.9 - 87.9)	76.8 (76.2 - 77.5)	51.6 (50.7 - 52.5)
DM	79.8 (78.9 - 80.8)	62.8 (61.6 - 63.9)	29.1 (28.0 - 30.3)
Non DM	88.4 (88.0 - 88.8)	78.7 (78.2 - 79.2)	54.8 (54.2 - 55.5)
All	87.1 (86.8 - 87.5)	76.1 (75.7 - 76.6)	50.0 (49.4 - 50.6)

Table A.5.5

**90-day, one- and two-year survival probabilities (cohort 1995-1999): Incident RRT patients, unadjusted***from day 1 to 90 days, one and two years, by age, gender and primary diagnosis*

	90 day Survival (95% CI)		1 year Survival (95% CI)		2 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	99.1	(98.2 - 99.5)	96.5	(95.2 - 97.5)	95.2	(93.7 - 96.3)
20-44	98.5	(98.2 - 98.8)	95.1	(94.6 - 95.6)	91.5	(91.0 - 92.1)
45-64	95.9	(95.6 - 96.2)	87.3	(86.8 - 87.7)	78.1	(77.6 - 78.5)
65-74	90.8	(90.4 - 91.2)	75.3	(74.8 - 75.8)	60.1	(59.6 - 60.6)
75+	86.4	(85.8 - 87.0)	66.2	(65.6 - 66.9)	48.1	(47.6 - 48.6)
Male	93.3	(93.0 - 93.5)	81.5	(81.2 - 81.9)	69.9	(69.5 - 70.2)
Female	92.9	(92.6 - 93.3)	80.9	(80.5 - 81.3)	69.4	(68.9 - 69.8)
DM	93.4	(93.0 - 93.9)	78.4	(77.8 - 79.1)	61.4	(60.8 - 62.0)
Non DM	92.9	(92.7 - 93.2)	81.7	(81.4 - 82.1)	71.5	(71.2 - 71.8)
All	93.1	(92.9 - 93.3)	81.3	(81.0 - 81.6)	69.7	(69.4 - 70.0)

Table A.5.6

**90-day, one- and two-year survival probabilities (cohort 1995-1999): Incident RRT patients, adjusted***from day 1 to 90 days, one and two years, adjusted for age, gender and primary diagnosis*

	90 day Survival (95% CI)		1 year Survival (95% CI)		2 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	98.9	(98.3 - 99.6)	96.1	(94.8 - 97.4)	94.5	(93.0 - 96.1)
20-44	98.5	(98.2 - 98.8)	95.1	(94.6 - 95.6)	91.5	(90.9 - 92.2)
45-64	96.0	(95.7 - 96.3)	87.5	(87.0 - 88.0)	78.6	(78.0 - 79.2)
65-74	90.9	(90.4 - 91.3)	75.7	(75.0 - 76.4)	60.7	(59.9 - 61.5)
75+	85.9	(85.2 - 86.7)	65.5	(64.5 - 66.5)	47.2	(46.1 - 48.2)
Male	94.9	(94.6 - 95.1)	85.4	(85.1 - 85.8)	75.2	(74.7 - 75.7)
Female	94.9	(94.6 - 95.1)	85.6	(85.2 - 86.1)	75.9	(75.3 - 76.5)
DM	94.7	(94.4 - 95.1)	82.2	(81.5 - 82.9)	66.6	(65.7 - 67.5)
Non DM	94.8	(94.6 - 95.0)	86.0	(85.7 - 86.4)	77.2	(76.8 - 77.7)
All	94.9	(94.7 - 95.0)	85.5	(85.2 - 85.8)	75.5	(75.1 - 75.9)

Table A.5.7

**One- and two-year survival probabilities (cohort 1995-1999): Incident RRT patients, unadjusted***from day 91 to one and two years + 90 days, by age, gender and primary diagnosis*

	<b>1 year Survival (95% CI)</b>		<b>2 year Survival (95% CI)</b>	
<b>ALL COUNTRIES</b>				
0-19	96.9	(95.5 - 97.9)	95.7	(94.1 - 96.8)
20-44	95.5	(95.0 - 95.9)	91.9	(91.3 - 92.5)
45-64	88.2	(87.8 - 88.6)	79.0	(78.5 - 79.4)
65-74	78.7	(78.1 - 79.2)	62.1	(61.6 - 62.6)
75+	71.2	(70.5 - 72.0)	51.0	(50.4 - 51.6)
Male	84.0	(83.6 - 84.3)	71.7	(71.3 - 72.1)
Female	83.6	(83.2 - 84.1)	71.5	(71.0 - 72.0)
DM	79.0	(78.4 - 79.7)	61.6	(61.0 - 62.2)
Non DM	84.9	(84.6 - 85.2)	74.0	(73.6 - 74.3)
All	83.8	(83.6 - 84.1)	71.6	(71.3 - 71.9)

Table A.5.8

**One- and two-year survival probabilities (cohort 1995-1999): Incident RRT patients, adjusted***from day 91 to one and two years + 90 days, adjusted for age, gender and primary diagnosis*

	<b>1 year Survival (95% CI)</b>		<b>2 year Survival (95% CI)</b>	
<b>ALL COUNTRIES</b>				
0-19	96.4	(95.1 - 97.8)	95.1	(93.5 - 96.6)
20-44	95.5	(95.1 - 96.0)	92.0	(91.4 - 92.7)
45-64	88.6	(88.1 - 89.1)	79.8	(79.2 - 80.4)
65-74	79.2	(78.5 - 79.9)	63.1	(62.3 - 64.0)
75+	70.6	(69.6 - 71.6)	50.4	(49.3 - 51.6)
Male	87.3	(86.9 - 87.6)	76.7	(76.2 - 77.2)
Female	87.6	(87.2 - 88.1)	77.6	(77.0 - 78.2)
DM	82.4	(81.7 - 83.1)	66.7	(65.8 - 67.7)
Non DM	88.3	(88.0 - 88.6)	79.0	(78.6 - 79.5)
All	87.4	(87.1 - 87.7)	77.0	(76.6 - 77.4)



Table A.5.9

**90-day, one-, two- and five-year survival probabilities (cohort 1992-1996): Incident dialysis patients, unadjusted***from day 1 to 90 days, one, two and five years, by age, gender and primary diagnosis*

	<b>90 day Survival (95% CI)</b>		<b>1 year Survival (95% CI)</b>		<b>2 year Survival (95% CI)</b>		<b>5 year Survival (95% CI)</b>	
<b>ALL COUNTRIES</b>								
0-19	99.3	(98.4 - 99.7)	96.9	(95.2 - 97.9)	94.2	(91.8 - 95.9)	88.5	(84.6 - 91.4)
20-44	98.7	(98.4 - 98.9)	95.0	(94.4 - 95.5)	89.8	(89.0 - 90.6)	74.6	(73.4 - 75.7)
45-64	95.8	(95.5 - 96.2)	86.7	(86.2 - 87.2)	75.4	(74.8 - 75.9)	47.0	(46.5 - 47.4)
65-74	91.9	(91.5 - 92.4)	76.2	(75.6 - 76.8)	59.6	(59.1 - 60.2)	26.9	(26.7 - 27.1)
75+	85.8	(85.0 - 86.6)	64.5	(63.7 - 65.4)	46.2	(45.5 - 46.8)	14.8	(14.6 - 14.9)
Male	93.8	(93.5 - 94.1)	81.9	(81.5 - 82.3)	68.1	(67.7 - 68.5)	36.9	(36.7 - 37.2)
Female	93.8	(93.4 - 94.1)	81.5	(81.0 - 82.1)	68.4	(67.8 - 68.9)	38.9	(38.6 - 39.3)
DM	93.6	(93.0 - 94.1)	76.7	(75.9 - 77.5)	57.3	(56.6 - 58.0)	22.4	(22.1 - 22.6)
Non DM	93.8	(93.5 - 94.0)	82.7	(82.3 - 83.1)	70.7	(70.3 - 71.0)	41.5	(41.2 - 41.8)
All	93.8	(93.6 - 94.0)	81.7	(81.4 - 82.1)	68.2	(67.9 - 68.6)	37.7	(37.5 - 37.9)

Table A.5.10

**90-day, one-, two- and five-year survival probabilities (cohort 1992-1996): Incident dialysis patients, adjusted***from day 1 to 90 days, one, two and five years, adjusted for age, gender and primary diagnosis*

	<b>90 day Survival (95% CI)</b>		<b>1 year Survival (95% CI)</b>		<b>2 year Survival (95% CI)</b>		<b>5 year Survival (95% CI)</b>	
<b>ALL COUNTRIES</b>								
0-19	99.1	(98.4 - 99.8)	96.3	(94.7 - 97.9)	93.2	(90.7 - 95.7)	84.9	(79.6 - 90.6)
20-44	98.7	(98.4 - 99.0)	95.0	(94.4 - 95.6)	89.7	(88.8 - 90.6)	72.9	(71.2 - 74.7)
45-64	95.9	(95.6 - 96.3)	87.1	(86.5 - 87.7)	76.0	(75.3 - 76.8)	46.3	(45.3 - 47.4)
65-74	92.0	(91.5 - 92.5)	76.5	(75.7 - 77.3)	60.0	(59.1 - 60.9)	26.4	(25.5 - 27.3)
75+	85.3	(84.3 - 86.3)	63.5	(62.2 - 64.8)	44.8	(43.5 - 46.2)	13.4	(12.5 - 14.3)
Male	94.6	(94.4 - 94.9)	84.2	(83.7 - 84.6)	71.9	(71.2 - 72.5)	40.9	(40.1 - 41.7)
Female	94.9	(94.5 - 95.2)	84.6	(84.0 - 85.2)	73.1	(72.4 - 73.9)	44.4	(43.5 - 45.4)
DM	94.3	(93.8 - 94.8)	78.9	(77.9 - 79.8)	60.6	(59.4 - 61.8)	24.5	(23.4 - 25.7)
Non DM	94.7	(94.5 - 95.0)	85.3	(84.9 - 85.7)	74.8	(74.2 - 75.3)	46.7	(46.0 - 47.5)
All	94.7	(94.5 - 94.9)	84.3	(84.0 - 84.7)	72.4	(71.9 - 72.9)	42.3	(41.7 - 43.0)

Table A.5.11

**One-, two- and five-year survival probabilities (cohort 1992-1996): Incident dialysis patients, unadjusted***from day 91 to one, two and five years + 90 days, by age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	96.5	(94.7 - 97.7)	94.7	(92.3 - 96.3)	88.8	(84.7 - 91.9)
20-44	95.0	(94.4 - 95.5)	89.9	(89.0 - 90.7)	73.8	(72.6 - 75.0)
45-64	87.5	(87.0 - 88.0)	76.0	(75.4 - 76.5)	46.5	(46.0 - 47.0)
65-74	78.2	(77.6 - 78.8)	60.9	(60.4 - 61.5)	27.1	(26.9 - 27.4)
75+	69.3	(68.4 - 70.2)	49.4	(48.7 - 50.2)	15.2	(15.0 - 15.4)
Male	83.5	(83.1 - 83.9)	69.3	(68.8 - 69.7)	36.9	(36.6 - 37.2)
Female	83.4	(82.9 - 83.9)	69.8	(69.3 - 70.4)	39.2	(38.8 - 39.5)
DM	76.4	(75.5 - 77.2)	57.0	(56.3 - 57.7)	21.4	(21.1 - 21.6)
Non DM	85.0	(84.6 - 85.4)	72.4	(72.0 - 72.8)	41.9	(41.6 - 42.2)
All	83.5	(83.1 - 83.8)	69.5	(69.1 - 69.9)	37.8	(37.6 - 38.1)

Table A.5.12

**One-, two- and five-year survival probabilities (cohort 1992-1996): Incident dialysis patients, adjusted***from day 91 to one, two and five years + 90 days, adjusted for age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	95.6	(93.7 - 97.6)	93.4	(90.8 - 96.0)	85.4	(80.0 - 91.1)
20-44	95.0	(94.4 - 95.6)	89.7	(88.8 - 90.7)	72.2	(70.4 - 74.1)
45-64	88.0	(87.4 - 88.5)	76.7	(76.0 - 77.5)	46.4	(45.3 - 47.5)
65-74	78.6	(77.8 - 79.4)	61.3	(60.4 - 62.3)	26.9	(26.0 - 27.8)
75+	68.3	(67.0 - 69.7)	47.9	(46.4 - 49.4)	14.0	(13.0 - 15.1)
Male	85.5	(85.0 - 86.0)	72.7	(72.0 - 73.3)	40.8	(39.9 - 41.6)
Female	86.0	(85.5 - 86.6)	74.2	(73.4 - 74.9)	44.6	(43.6 - 45.7)
DM	78.3	(77.3 - 79.3)	60.0	(58.8 - 61.2)	23.5	(22.3 - 24.7)
Non DM	87.1	(86.7 - 87.5)	76.0	(75.4 - 76.5)	47.0	(46.3 - 47.8)
All	85.7	(85.3 - 86.1)	73.3	(72.8 - 73.8)	42.3	(41.7 - 43.0)

Table A.5.13

**90-day, one- and two-year survival probabilities (cohort 1995-1999): Incident dialysis patients, unadjusted***from day 1 to 90 days, one and two years, by age, gender and primary diagnosis*

	90 day Survival (95% CI)		1 year Survival (95% CI)		2 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	98.9	(97.9 - 99.5)	96.0	(94.2 - 97.2)	94.5	(92.3 - 96.0)
20-44	98.5	(98.2 - 98.8)	94.6	(94.1 - 95.1)	90.0	(89.3 - 90.7)
45-64	95.9	(95.6 - 96.1)	86.9	(86.5 - 87.4)	76.5	(76.0 - 77.0)
65-74	91.0	(90.6 - 91.4)	75.6	(75.0 - 76.1)	60.1	(59.6 - 60.6)
75+	86.7	(86.1 - 87.3)	66.7	(66.1 - 67.4)	48.7	(48.2 - 49.2)
Male	93.2	(93.0 - 93.5)	81.0	(80.6 - 81.3)	67.8	(67.4 - 68.2)
Female	92.9	(92.6 - 93.2)	80.5	(80.1 - 81.0)	67.6	(67.1 - 68.1)
DM	93.4	(93.0 - 93.9)	78.1	(77.5 - 78.8)	59.9	(59.3 - 60.5)
Non DM	92.9	(92.6 - 93.1)	81.2	(80.9 - 81.6)	69.6	(69.3 - 69.9)
All	93.1	(92.9 - 93.3)	80.8	(80.5 - 81.1)	67.7	(67.4 - 68.0)

Table A.5.14

**90-day, one- and two-year survival probabilities (cohort 1995-1999): Incident dialysis patients, adjusted***from day 1 to 90 days, one and two years, adjusted for age, gender and primary diagnosis*

	90 day Survival (95% CI)		1 year Survival (95% CI)		2 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	98.8	(98.0 - 99.6)	95.4	(93.7 - 97.2)	93.5	(91.3 - 95.8)
20-44	98.5	(98.2 - 98.8)	94.6	(94.1 - 95.2)	90.0	(89.2 - 90.8)
45-64	95.9	(95.6 - 96.2)	87.3	(86.7 - 87.8)	77.1	(76.5 - 77.8)
65-74	91.0	(90.5 - 91.5)	75.9	(75.2 - 76.6)	60.6	(59.8 - 61.4)
75+	86.2	(85.5 - 86.9)	66.0	(65.0 - 67.0)	47.7	(46.6 - 48.7)
Male	94.5	(94.3 - 94.8)	84.4	(84.0 - 84.8)	73.3	(72.7 - 73.8)
Female	94.5	(94.2 - 94.8)	84.7	(84.2 - 85.2)	74.0	(73.4 - 74.7)
DM	94.5	(94.1 - 94.9)	81.2	(80.5 - 82.0)	64.8	(63.9 - 65.7)
Non DM	94.4	(94.2 - 94.7)	85.1	(84.8 - 85.5)	75.4	(74.9 - 75.9)
All	94.5	(94.3 - 94.7)	84.6	(84.2 - 84.9)	73.6	(73.1 - 74.0)

Table A.5.15

**One- and two-year survival probabilities (cohort 1995-1999): Incident dialysis patients, unadjusted***from day 91 to one and two years + 90 days, by age, gender and primary diagnosis*

	<b>1 year Survival (95% CI)</b>		<b>2 year Survival (95% CI)</b>	
<b>ALL COUNTRIES</b>				
0-19	96.7	(94.9 - 97.8)	94.9	(92.6 - 96.5)
20-44	94.9	(94.4 - 95.4)	90.1	(89.4 - 90.8)
45-64	87.7	(87.3 - 88.2)	77.1	(76.6 - 77.7)
65-74	78.7	(78.2 - 79.3)	61.9	(61.4 - 62.4)
75+	71.6	(70.9 - 72.3)	51.5	(50.9 - 52.0)
Male	83.3	(82.9 - 83.6)	69.2	(68.8 - 69.6)
Female	83.1	(82.6 - 83.5)	69.3	(68.8 - 69.8)
DM	78.6	(77.9 - 79.2)	59.7	(59.1 - 60.3)
Non DM	84.3	(83.9 - 84.6)	71.7	(71.3 - 72.0)
All	83.2	(82.9 - 83.5)	69.3	(69.0 - 69.6)

Table A.5.16

**One- and two-year survival probabilities (cohort 1995-1999): Incident dialysis patients, adjusted***from day 91 to one and two years + 90 days, adjusted for age, gender and primary diagnosis*

	<b>1 year Survival (95% CI)</b>		<b>2 year Survival (95% CI)</b>	
<b>ALL COUNTRIES</b>				
0-19	96.3	(94.6 - 98.0)	94.1	(91.8 - 96.5)
20-44	94.9	(94.4 - 95.5)	90.2	(89.4 - 91.0)
45-64	88.2	(87.7 - 88.7)	78.1	(77.4 - 78.8)
65-74	79.2	(78.5 - 79.9)	62.9	(62.0 - 63.7)
75+	71.0	(70.0 - 72.0)	50.9	(49.7 - 52.0)
Male	86.3	(85.9 - 86.7)	74.5	(73.9 - 75.1)
Female	86.6	(86.2 - 87.1)	75.5	(74.8 - 76.1)
DM	81.4	(80.6 - 82.1)	64.7	(63.7 - 65.7)
Non DM	87.3	(87.0 - 87.7)	77.0	(76.5 - 77.5)
All	86.4	(86.1 - 86.8)	74.9	(74.5 - 75.4)

Table A.5.17

**One-, two- and five-year survival probabilities (cohort 1992-1996): First transplant patients (cadaver donor), unadjusted***from day of transplant to one, two and five years, by age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	96.5	(94.7 - 97.7)	95.8	(93.9 - 97.1)	94.1	(92.0 - 95.6)
20-44	96.8	(96.2 - 97.3)	95.1	(94.4 - 95.8)	90.1	(89.2 - 91.0)
45-64	92.0	(91.2 - 92.7)	88.7	(87.8 - 89.5)	77.7	(76.7 - 78.7)
65+	87.4	(84.3 - 89.9)	82.4	(79.2 - 85.2)	63.0	(60.0 - 65.8)
Male	94.0	(93.4 - 94.6)	91.4	(90.7 - 92.1)	82.5	(81.6 - 83.3)
Female	94.2	(93.4 - 94.9)	91.8	(90.9 - 92.7)	84.6	(83.5 - 85.7)
DM	91.7	(90.0 - 93.2)	86.8	(84.8 - 88.5)	74.5	(72.4 - 76.5)
Non DM	94.2	(93.6 - 94.7)	92.0	(91.4 - 92.6)	84.4	(83.6 - 85.1)
All	94.1	(93.6 - 94.5)	91.6	(91.0 - 92.1)	83.3	(82.6 - 83.9)

Table A.5.18

**One-, two- and five-year survival probabilities (cohort 1992-1996): First transplant patients (cadaver donor), adjusted***from day of transplant to one, two and five years, adjusted for age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	96.1	(94.5 - 97.8)	95.4	(93.6 - 97.2)	93.4	(91.3 - 95.6)
20-44	97.0	(96.4 - 97.5)	95.4	(94.8 - 96.1)	90.7	(89.8 - 91.7)
45-64	91.9	(91.1 - 92.8)	88.7	(87.7 - 89.7)	78.0	(76.7 - 79.4)
65+	87.4	(84.3 - 90.7)	82.7	(79.1 - 86.4)	63.1	(58.6 - 67.9)
Male	94.9	(94.3 - 95.5)	92.7	(92.0 - 93.4)	84.9	(83.9 - 85.9)
Female	94.8	(94.1 - 95.6)	92.7	(91.8 - 93.6)	86.1	(84.9 - 87.3)
DM	91.8	(90.1 - 93.6)	86.9	(84.8 - 89.0)	74.3	(71.6 - 77.1)
Non DM	95.1	(94.6 - 95.6)	93.2	(92.6 - 93.7)	86.3	(85.4 - 87.1)
All	94.9	(94.4 - 95.4)	92.7	(92.2 - 93.3)	85.4	(84.6 - 86.2)

Table A.5.19

**One- and two-year survival probabilities (cohort 1995-1999): First transplant patients (cadaver donor), unadjusted***from day of transplant to one and two years, by age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)	
<b>ALL COUNTRIES</b>				
0-19	97.3	(95.6 - 98.3)	95.9	(93.9 - 97.2)
20-44	97.4	(96.9 - 97.9)	96.2	(95.6 - 96.8)
45-64	94.1	(93.4 - 94.7)	91.5	(90.7 - 92.2)
65+	85.7	(83.0 - 88.0)	81.0	(78.2 - 83.5)
Male	94.9	(94.4 - 95.4)	92.8	(92.1 - 93.4)
Female	95.5	(94.8 - 96.1)	93.5	(92.7 - 94.2)
DM	93.0	(91.5 - 94.3)	90.5	(88.7 - 91.9)
Non DM	95.4	(94.9 - 95.8)	93.4	(92.9 - 93.9)
All	95.1	(94.7 - 95.5)	93.0	(92.5 - 93.5)

Table A.5.20

**One- and two-year survival probabilities (cohort 1995-1999): First transplant patients (cadaver donor), adjusted***from day of transplant to one and two years, adjusted for age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)	
<b>ALL COUNTRIES</b>				
0-19	97.2	(95.8 - 98.7)	95.7	(93.9 - 97.5)
20-44	97.5	(97.0 - 98.0)	96.4	(95.8 - 97.0)
45-64	94.2	(93.5 - 94.9)	91.7	(90.8 - 92.5)
65+	85.4	(82.5 - 88.5)	81.2	(78.0 - 84.6)
Male	95.9	(95.5 - 96.4)	94.2	(93.6 - 94.8)
Female	96.0	(95.4 - 96.6)	94.4	(93.6 - 95.1)
DM	93.2	(91.8 - 94.7)	90.8	(89.1 - 92.5)
Non DM	96.2	(95.8 - 96.6)	94.5	(94.0 - 95.0)
All	96.0	(95.6 - 96.4)	94.2	(93.8 - 94.7)

Table A.5.21

**One-, two- and five-year survival probabilities (cohort 1992-1996): First transplant patients (living donor), unadjusted***from day of transplant to one, two and five years, by age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	98.3	(96.1 - 99.3)	98.0	(95.7 - 99.1)	97.4	(94.9 - 98.6)
20-44	98.8	(97.9 - 99.3)	97.5	(96.4 - 98.2)	93.9	(92.4 - 95.1)
45-64	96.2	(94.1 - 97.6)	95.6	(93.3 - 97.1)	89.4	(86.5 - 91.6)
65+	83.3	(71.3 - 90.6)	76.2	(64.6 - 84.4)	64.3	(54.2 - 72.7)
Male	97.6	(96.5 - 98.3)	96.9	(95.7 - 97.7)	93.0	(91.5 - 94.3)
Female	98.1	(96.8 - 98.8)	96.3	(94.7 - 97.4)	92.2	(90.2 - 93.8)
DM	95.6	(91.3 - 97.8)	92.5	(87.6 - 95.5)	81.1	(75.6 - 85.5)
Non DM	97.9	(97.2 - 98.5)	97.0	(96.1 - 97.7)	93.8	(92.6 - 94.8)
All	97.7	(97.0 - 98.3)	96.6	(95.7 - 97.3)	92.7	(91.5 - 93.7)

Table A.5.22

**One-, two- and five-year survival probabilities (cohort 1992-1996): First transplant patients (living donor), adjusted***from day of transplant to one, two and five years, adjusted for age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	-	-	-	-	-	-
20-44	98.9	(98.3 - 99.5)	97.6	(96.8 - 98.5)	94.3	(92.9 - 95.7)
45-64	96.5	(94.9 - 98.2)	95.9	(94.1 - 97.7)	90.1	(87.4 - 92.8)
65+	-	-	-	-	-	-
Male	97.2	(96.1 - 98.2)	96.3	(95.1 - 97.5)	91.7	(89.9 - 93.5)
Female	97.6	(96.3 - 98.8)	95.3	(93.6 - 97.1)	90.2	(87.7 - 92.7)
DM	95.1	(91.6 - 98.7)	91.6	(87.2 - 96.2)	79.0	(72.6 - 85.9)
Non DM	97.4	(96.5 - 98.2)	96.2	(95.1 - 97.2)	91.9	(90.5 - 93.4)
All	97.3	(96.5 - 98.1)	95.9	(95.0 - 96.9)	91.1	(89.7 - 92.6)

Table A.5.23

**One- and two-year survival probabilities (cohort 1995-1999): First transplant patients (living donor), unadjusted***from day of transplant to one and two years, by age, gender and primary diagnosis*

	<b>1 year Survival (95% CI)</b>		<b>2 year Survival (95% CI)</b>	
<b>ALL COUNTRIES</b>				
0-19	98.2	(96.2 - 99.2)	97.7	(95.4 - 98.8)
20-44	98.8	(98.0 - 99.3)	98.1	(97.1 - 98.7)
45-64	95.9	(94.2 - 97.2)	95.6	(93.8 - 96.9)
65+	90.3	(81.1 - 95.2)	87.1	(77.7 - 92.7)
Male	98.0	(97.2 - 98.6)	97.7	(96.8 - 98.3)
Female	97.1	(95.7 - 98.0)	95.9	(94.3 - 97.0)
DM	97.3	(93.7 - 98.8)	96.2	(92.3 - 98.1)
Non DM	97.7	(97.0 - 98.3)	97.1	(96.3 - 97.7)
All	97.7	(97.0 - 98.2)	97.0	(96.3 - 97.6)

Table A.5.24

**One- and two-year survival probabilities (cohort 1995-1999): First transplant patients (living donor), adjusted***from day of transplant to one and two years, adjusted for age, gender and primary diagnosis*

	<b>1 year Survival (95% CI)</b>		<b>2 year Survival (95% CI)</b>	
<b>ALL COUNTRIES</b>				
0-19		-		-
20-44	98.8	(98.3 - 99.4)	98.2	(97.4 - 98.9)
45-64	95.9	(94.4 - 97.5)	95.6	(94.1 - 97.2)
65+		-		-
Male	97.8	(97.0 - 98.6)	97.4	(96.5 - 98.3)
Female	96.5	(95.1 - 97.9)	95.0	(93.3 - 96.6)
DM		-		-
Non DM	97.3	(96.5 - 98.1)	96.6	(95.7 - 97.4)
All	97.3	(96.6 - 98.0)	96.5	(95.7 - 97.4)



Table A.5.25

**One-, two- and five-year survival probabilities (cohort 1992-1996): First graft (cadaver donor), unadjusted**

*from day of transplant to one, two and five years, by age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	80.6	(77.7 - 83.2)	76.8	(73.9 - 79.4)	64.7	(62.0 - 67.3)
20-44	87.1	(86.1 - 88.1)	83.5	(82.4 - 84.5)	72.6	(71.5 - 73.6)
45-64	83.4	(82.4 - 84.3)	79.9	(78.9 - 80.9)	67.6	(66.6 - 68.6)
65+	82.2	(79.0 - 85.0)	77.3	(74.0 - 80.2)	57.1	(54.4 - 59.7)
Male	84.8	(83.9 - 85.6)	81.0	(80.2 - 81.9)	68.3	(67.5 - 69.2)
Female	84.6	(83.5 - 85.6)	81.1	(79.9 - 82.2)	69.9	(68.8 - 71.1)
DM	83.3	(81.2 - 85.1)	77.6	(75.5 - 79.6)	64.6	(62.6 - 66.5)
Non DM	84.6	(83.9 - 85.3)	81.2	(80.5 - 82.0)	69.4	(68.7 - 70.2)
All	84.7	(84.0 - 85.3)	81.1	(80.4 - 81.7)	68.9	(68.2 - 69.6)

Table A.5.26

**One-, two- and five-year survival probabilities (cohort 1992-1996): First graft (cadaver donor), adjusted**

*from day of transplant to one, two and five years, adjusted for age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	80.1	(76.6 - 83.7)	76.0	(72.3 - 79.9)	64.4	(60.3 - 68.8)
20-44	87.3	(86.1 - 88.4)	83.7	(82.5 - 85.0)	73.1	(71.6 - 74.7)
45-64	83.1	(81.9 - 84.3)	79.6	(78.3 - 80.9)	67.5	(66.0 - 69.1)
65+	82.3	(78.8 - 86.1)	78.0	(74.2 - 82.1)	57.7	(53.1 - 62.6)
Male	84.7	(83.7 - 85.7)	81.0	(79.9 - 82.1)	68.6	(67.3 - 69.9)
Female	84.4	(83.0 - 85.7)	80.8	(79.4 - 82.3)	69.7	(68.1 - 71.4)
DM	83.0	(80.7 - 85.5)	77.3	(74.7 - 80.0)	64.1	(61.1 - 67.3)
Non DM	84.7	(83.8 - 85.5)	81.3	(80.4 - 82.3)	69.5	(68.4 - 70.6)
All	84.6	(83.8 - 85.4)	81.0	(80.1 - 81.9)	69.1	(68.0 - 70.1)

Table A.5.27

**One- and two-year survival probabilities (cohort 1995-1999): First graft (cadaver donor), unadjusted**

*from day of transplant to one and two years, by age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)	
<b>ALL COUNTRIES</b>				
0-19	85.2	(82.3 - 87.7)	81.3	(78.3 - 83.9)
20-44	90.0	(89.1 - 90.8)	87.5	(86.6 - 88.4)
45-64	87.4	(86.5 - 88.2)	84.0	(83.1 - 84.9)
65+	80.9	(78.1 - 83.4)	75.0	(72.2 - 77.6)
Male	88.1	(87.4 - 88.9)	84.9	(84.1 - 85.6)
Female	87.6	(86.6 - 88.5)	84.4	(83.4 - 85.4)
DM	87.2	(85.3 - 88.8)	83.7	(81.7 - 85.4)
Non DM	87.9	(87.2 - 88.5)	84.7	(84.0 - 85.4)
All	87.9	(87.3 - 88.5)	84.7	(84.1 - 85.3)

Table A.5.28

**One- and two-year survival probabilities (cohort 1995-1999): First graft (cadaver donor), adjusted**

*from day of transplant to one and two years, adjusted for age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)	
<b>ALL COUNTRIES</b>				
0-19	85.4	(82.2 - 88.6)	81.5	(78.1 - 85.1)
20-44	90.0	(89.0 - 91.0)	87.6	(86.5 - 88.7)
45-64	87.3	(86.3 - 88.3)	83.9	(82.8 - 85.0)
65+	80.7	(77.4 - 84.1)	75.4	(71.8 - 79.1)
Male	88.3	(87.4 - 89.2)	85.1	(84.2 - 86.1)
Female	87.4	(86.3 - 88.6)	84.4	(83.2 - 85.6)
DM	86.9	(84.9 - 89.0)	83.5	(81.3 - 85.8)
Non DM	88.0	(87.3 - 88.8)	84.9	(84.1 - 85.7)
All	88.0	(87.3 - 88.6)	84.8	(84.1 - 85.6)

Table A.5.29

**One-, two- and five-year survival probabilities (cohort 1992-1996): First graft (living donor), unadjusted**

*from day of transplant to one, two and five years, by age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	93.3	(89.8 - 95.6)	91.4	(87.7 - 94.0)	81.3	(77.1 - 84.8)
20-44	92.9	(91.2 - 94.2)	89.5	(87.7 - 91.1)	80.5	(78.5 - 82.4)
45-64	91.2	(88.4 - 93.3)	89.8	(86.9 - 92.1)	82.3	(79.2 - 85.0)
65+	82.9	(70.7 - 90.4)	73.2	(61.7 - 81.7)	61.0	(51.2 - 69.4)
Male	92.6	(91.1 - 94.0)	89.6	(87.9 - 91.1)	80.4	(78.4 - 82.2)
Female	91.7	(89.6 - 93.4)	89.4	(87.1 - 91.2)	81.0	(78.5 - 83.3)
DM	90.4	(85.2 - 93.8)	85.3	(79.8 - 89.4)	73.7	(68.2 - 78.4)
Non DM	92.5	(91.2 - 93.6)	89.9	(88.5 - 91.2)	81.3	(79.7 - 82.8)
All	92.3	(91.0 - 93.3)	89.5	(88.2 - 90.7)	80.6	(79.1 - 82.1)

Table A.5.30

**One-, two- and five-year survival probabilities (cohort 1992-1996): First graft (living donor), adjusted**

*from day of transplant to one, two and five years, adjusted for age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)		5 year Survival (95% CI)	
<b>ALL COUNTRIES</b>						
0-19	92.9	(89.8 - 96.1)	90.9	(87.4 - 94.5)	80.3	(75.5 - 85.3)
20-44	92.9	(91.3 - 94.5)	89.7	(87.9 - 91.6)	80.7	(78.3 - 83.1)
45-64	91.4	(88.8 - 94.0)	90.0	(87.3 - 92.8)	82.7	(79.3 - 86.3)
65+	-	-	-	-	-	-
Male	92.0	(90.3 - 93.7)	88.9	(86.9 - 90.9)	79.1	(76.5 - 81.7)
Female	91.1	(88.9 - 93.4)	88.6	(86.1 - 91.2)	79.5	(76.3 - 82.9)
DM	90.0	(85.4 - 94.9)	84.7	(79.2 - 90.7)	72.9	(66.1 - 80.3)
Non DM	91.8	(90.3 - 93.2)	89.1	(87.5 - 90.8)	79.8	(77.6 - 82.1)
All	91.7	(90.3 - 93.1)	88.8	(87.2 - 90.4)	79.3	(77.1 - 81.5)

Table A.5.31

**One- and two-year survival probabilities (cohort 1995-1999): First graft (living donor), unadjusted**

*from day of transplant to one and two years, by age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)	
<b>ALL COUNTRIES</b>				
0-19	93.3	(90.0 - 95.5)	90.9	(87.4 - 93.4)
20-44	94.5	(93.2 - 95.6)	92.8	(91.3 - 94.1)
45-64	91.9	(89.7 - 93.7)	91.0	(88.7 - 92.8)
65+	90.3	(81.1 - 95.2)	87.1	(77.7 - 92.7)
Male	94.5	(93.3 - 95.5)	93.2	(91.9 - 94.3)
Female	91.7	(89.7 - 93.3)	89.5	(87.4 - 91.2)
DM	92.7	(88.1 - 95.5)	90.4	(85.6 - 93.6)
Non DM	93.6	(92.5 - 94.5)	92.0	(90.8 - 93.0)
All	93.5	(92.4 - 94.4)	91.9	(90.7 - 92.9)

Table A.5.32

**One- and two-year survival probabilities (cohort 1995-1999): First graft (living donor), adjusted**

*from day of transplant to one and two years, adjusted for age, gender and primary diagnosis*

	1 year Survival (95% CI)		2 year Survival (95% CI)	
<b>ALL COUNTRIES</b>				
0-19	93.0	(90.1 - 96.0)	90.6	(87.3 - 94.0)
20-44	94.6	(93.3 - 95.9)	92.9	(91.4 - 94.4)
45-64	91.8	(89.7 - 94.0)	90.9	(88.6 - 93.2)
65+	-	-	-	-
Male	94.3	(93.0 - 95.6)	92.9	(91.5 - 94.3)
Female	91.2	(89.2 - 93.3)	88.9	(86.6 - 91.3)
DM	92.4	(88.6 - 96.5)	90.1	(85.8 - 94.7)
Non DM	93.2	(92.1 - 94.4)	91.6	(90.3 - 92.9)
All	93.2	(92.0 - 94.3)	91.5	(90.2 - 92.7)

## **IV Reference tables – SECTION B**

Table B.1.1

**General population of the country/region and percent coverage of general population in 2001**

	<b>General population in thousands</b>	<b>% Coverage of general population</b>
Bosnia-Herzegovina	3,700.0	
Croatia	4,437.0	100
Czech Republic	10,200.0	
Estonia		
Germany	82,440.3	93
Russia	146,934.0	100
Serbia and Montenegro	10,651.7	
Tunisia	9,673.6	100
Turkey	67,800.0	

Table B.1.2

**Renal centres: total number of centres and number collaborating**

	<b>Total number of renal centres</b>	<b>Number of renal centres collaborating with the registry</b>
Bosnia-Herzegovina	21	19
Croatia	40	40
Czech Republic	93	93
Estonia		
Germany	1164	1077
Russia	299	270
Serbia and Montenegro	56	52
Tunisia	121	121
Turkey	424	364

*The number of renal centres is based on having a separate centre code*

Table B.2.1  
**Incident counts and incident rates per million population, unadjusted**  
*at day 1*

	All		Men		Women	
	N	Pmp	N	Pmp	N	Pmp
Bosnia-Herzegovina	226	61.0				
Croatia	498	112.2	269	125.9	229	99.5
Czech Republic	1622	162.9				
Estonia						
Germany	150148	184.0	8725	217.0	6423	152.0
Russia	2266	15.4	1292		974	
Serbia and Montenegro	979	91.9				
Tunisia	1165	120.4	653	133.8	512	106.7
Turkey						



Table B.2.2

**Gender, mean and median age of incident patients***at day 1*

	All			Men			Women		
	%	Mean years (SD)	Median years	%	Mean years (SD)	Median years	%	Mean years (SD)	Median years
Bosnia-Herzegovina									
Croatia	100	60.0 ( - )	62.0	54	58.7 ( - )	61.0	46	61.0 ( - )	64.0
Czech Republic									
Estonia									
Germany	100	64.0 (14.5)	67.0	58	63.0 (14.4)	65.0	42	66.0 (14.6)	69.0
Russia	100	43.8 (15.2)	45.0	57	43.7 (14.9)	44.0	43	44.0 (15.6)	46.0
Serbia and Montenegro		49.5 (14.1)	59.0						
Tunisia	100	52.0 ( - )	55.7	56	52.1 ( - )	55.0	44	53.0 ( - )	56.1
Turkey									

Table B.2.3  
**Incident rates per million population, adjusted**

*at day 1, adjusted for age and gender*

	<b>All</b>	<b>Men</b>	<b>Women</b>
	<b>Pmp</b>	<b>Pmp</b>	<b>Pmp</b>
Bosnia-Herzegovina			
Croatia	106.9	128.8	86.5
Czech Republic			
Estonia			
Germany	171.0	219.0	126.0
Russia			
Serbia and Montenegro			
Tunisia	120.4	133.9	106.7
Turkey			

Table B.2.4  
**Incident rates per million population and percentage, unadjusted**  
*at day 1, by cause of renal failure*

	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing	
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Type I		Type II		Both		Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%
									Pmp	%	Pmp	%	Pmp	%										
Bosnia-Herzegovina																								
Croatia	112.2	100	17.8	16	12.6	11	7.7	7					32.7	29	15.3	14	3.2	3	14.6	13	4.3	4	4.1	4
Czech Republic	162.9	100											55.4	34										
Estonia																								
Germany	184.0	100	26.0	14	12.0	6	7.0	4	8.0	4	58.0	32	66.0	36	19.0	10	11.0	6	26.0	14	17.0	10		
Russia	15.4	100	6.9	45	1.8	12	1.5	10	1.2	8	0.5	3	1.7	11	0.6	4	0.1	1	2.2	14	0.2	1	0.4	3
Serbia and Montenegro	91.9	100	20.2	22	13.8	15	6.4	7					7.4	8	15.6	17			20.2	22	8.3	9		
Tunisia	120.4	100	12.8	11	11.9	10	1.4	1					24.7	21	15.6	13	2.7	2	11.2	9	40.1	33		
Turkey																								

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown

Table B.3.1  
**Incident counts and incident rates per million population, unadjusted**  
*at day 90*

	All		Men		Women	
	N	Pmp	N	Pmp	N	Pmp
Bosnia-Herzegovina						
Croatia	466	105.0	252	118.0	214	93.0
Czech Republic						
Estonia						
Germany						
Russia	1976	13.4	1132		844	
Serbia and Montenegro						
Tunisia	913	94.4	522	107.0	391	81.5
Turkey	9498	142.0	5526		3972	

Table B.3.2

**Gender, mean and median age of incident patients***at day 90*

	All			Men			Women		
	%	Mean years (SD)	Median years	%	Mean years (SD)	Median years	%	Mean years (SD)	Median years
Bosnia-Herzegovina									
Croatia	100	59.4 ( - )	63.0	54	57.9 ( - )	61.0	46	61.2 ( - )	64.0
Czech Republic									
Estonia									
Germany									
Russia	100	43.3 (15.1)	45.0	57	43.2 (14.8)	44.0	42	43.7 (15.6)	46.0
Serbia and Montenegro									
Tunisia	100	52.5 ( - )	56.0	57	52.1 ( - )	55.1	43	52.9 ( - )	56.4
Turkey	100			58			42		

Table B.3.3  
**Incident rates per million population, adjusted**  
*at day 90, adjusted for age and gender*

	<b>All</b>	<b>Men</b>	<b>Women</b>
	<b>Pmp</b>	<b>Pmp</b>	<b>Pmp</b>
Bosnia-Herzegovina			
Croatia	100.1	120.9	80.8
Czech Republic			
Estonia			
Germany			
Russia			
Serbia and Montenegro			
Tunisia	94.4	107.1	81.5
Turkey	144.0		

Table B.3.4  
**Incident rates per million population and percentage, unadjusted**  
*at day 90, by cause of renal failure*

	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing	
									Type I		Type II		Both											
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%
Bosnia-Herzegovina																								
Croatia	105.0	100	18.7	18	10.8	10	8.1	8					30.0	29	14.2	14	2.9	3	14.4	14	3.4	3	2.5	2
Czech Republic																								
Estonia																								
Germany																								
Russia	13.4	100	6.1	46	1.5	11	1.3	10	1.1	8	0.4	3	1.5	12	0.6	4	0.1	1	1.9	14	0.2	1	0.3	3
Serbia and Montenegro																								
Tunisia	94.4	100	10.3	11	9.7	10	1.0	1					20.0	21	11.8	13	2.3	2	9.0	10	30.3	32		
Turkey	144.0	100	27.4	19	5.0	4	7.3	5					31.7	22	21.4	15			16.5	11	34.4	24		

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown

Table B.3.5  
Incident counts

*at day 90, by established therapy*

	Total	Haemodialysis						Peritoneal dialysis				Transplant			Missing	
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver	Tx, type unknown		Total Tx
Bosnia-Herzegovina																
Croatia	466	412	0	0	0	0	412	1	51	0	52	1	1	0	2	0
Czech Republic				1532							130					
Estonia																
Germany																
Russia	1976	1794	0	0	0	0	1794	0	179	0	179	0	3	0	3	0
Serbia and Montenegro																
Tunisia	913	853					853	6	54		60					
Turkey	9683	8330					8330	185	752		973	320	155		475	



Table B.3.6

**Incident rates per million population, unadjusted***at day 90, by established therapy*

	Total	Haemodialysis						Peritoneal dialysis				Transplant			Missing	
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver	Tx, type unknown		Total Tx
Bosnia-Herzegovina																
Croatia	105.0	92.9	0.0	0.0	0.0	0.0	92.9	0.2	11.5	0.0	11.7	0.2	0.2	0.0	0.5	0.0
Czech Republic	162.9						150.2				12.7				0.0	
Estonia																
Germany																
Russia	13.4	12.2	0.0	0.0	0.0	0.0	12.2	0.0	1.2	0.0	1.2	0.0	0.0	0.0	0.0	0.0
Serbia and Montenegro																
Tunisia	94.4	88.2	0.0	0.0	0.0	0.0	88.2	0.6	5.6	0.0	6.2	0.0	0.0	0.0	0.0	0.0
Turkey	144.0	122.0					122.0	2.7	11.1		13.8	4.7	2.3		7.0	

Table B.3.7

**Percentage of established therapy, unadjusted***at day 90*

	Total	Haemodialysis					Peritoneal dialysis				Transplant			Missing		
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver		Tx, type unknown	Total Tx
	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%
Bosnia-Herzegovina																
Croatia	100.0	88.4	0.0	0.0	0.0	0.0	88.4	0.2	10.9	0.0	11.2	0.2	0.2	0.0	0.4	0.0
Czech Republic	100.0						92.2				7.8				0.0	
Estonia																
Germany																
Russia	100.0	90.8	0.0	0.0	0.0	0.0	90.8	0.0	9.1	0.0	9.1	0.0	0.2	0.0	0.2	0.0
Serbia and Montenegro																
Tunisia	100.0	93.4	0.0	0.0	0.0	0.0	93.4	0.7	5.9	0.0	6.6	0.0	0.0	0.0	0.0	0.0
Turkey	100.0	86.0					86.0	1.9	7.8		9.6	3.3	1.6		4.9	

Table B.4.1

**Prevalent counts and per million population, unadjusted***prevalent patients on December 31*

	All		Men		Women	
	N	Pmp	N	Pmp	N	Pmp
Bosnia-Herzegovina	1351	365.0				
Croatia	2913	656.5	1660	749.0	1253	544.3
Czech Republic	6759	662.6				
Estonia	332	245.0	181		151	
Germany	75672	919.0	42982	1067.0	32690	775.0
Germany (on dialysis)	57188	695.0	32483	807.0	24705	586.0
Russia	10731	73.0	5792		4939	
Serbia and Montenegro	4224	396.6	2323	440.0	1901	354.0
Tunisia	4932	509.8	2748	563.1	2184	455.0
Turkey	24492	361.0	13623		10869	

Table B.4.2  
**Gender, mean and median age**  
*prevalent patients on December 31*

	All			Men			Women		
	%	Mean years (SD)	Median years	%	Mean years (SD)	Median years	%	Mean years (SD)	Median years
Bosnia-Herzegovina									
Croatia	100	55.2 ( - )	57.0	57	54.2 ( - )	56.0	43	56.7 ( - )	59.0
Czech Republic									
Estonia	100		52.1	55		52.4	46		51.8
Germany	100	60.1 (15.8)	63.0	57	58.8 (15.5)	62.0	43	61.7 (16.2)	65.0
Russia	100	44.5 (13.5)	45.0	54	44.5 (13.7)	45.0	46	44.4 (13.4)	46.0
Serbia and Montenegro	100	48.2 (13.8)	55.0	55			45		
Tunisia	100	51.6 ( - )	53.1	56	50.8 ( - )	51.9	44	52.6 ( - )	55.0
Turkey	100			56			44		

Table B.4.3

**Prevalence per million population, adjusted***prevalent patients on December 31, adjusted for age and gender*

	<b>All</b>	<b>Men</b>	<b>Women</b>
	<b>Pmp</b>	<b>Pmp</b>	<b>Pmp</b>
Bosnia-Herzegovina			
Croatia	627.0	773.2	491.1
Czech Republic			
Estonia			
Germany	852.0	1049.0	663.0
Russia			
Serbia and Montenegro			
Tunisia	509.8	563.7	455.2
Turkey			

Table B.4.4

**Prevalence per million population and percentage, unadjusted***prevalent patients on December 31, by cause of renal failure*

	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing			
									Type I			Type II			Both											
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%		
Bosnia-Herzegovina																										
Croatia	657.0	100	182.0	28	116.0	18	58.0	9							92.0	14	49.0	7	11.0	2	89.0	14	58.0	9	5.0	1
Czech Republic																										
Estonia	245.0	100		33		22		9						18		7					11					
Germany	919.0	100	222.0	24	99.0	11	55.0	6	47.0	5	155.0	17	202.0	22	58.0	6	35.0	4	151.0	16	97.0	11				
Russia	73.0	100	38.5	53	6.8	9	5.7	8	2.7	4	0.7	1	3.4	5	1.2	2	0.1	0	6.9	9	2.4	3	8.0	11		
Serbia and Montenegro	396.6	100	107.1	27	55.5	14	39.7	10					31.7	8	51.6	13			79.3	20	31.7	8				
Tunisia	509.8	100	78.8	15	65.3	13	9.8	2					69.9	14	84.0	17	11.1	2	56.5	11	134.4	26				
Turkey																										

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown

Table B.4.5

**Prevalence counts***prevalent patients on December 31, by established therapy*

	Total	Haemodialysis					Peritoneal dialysis				Transplant			Missing		
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver		Tx, type unknown	Total Tx
Bosnia-Herzegovina	1351						1143				27				110	71
Croatia	2913	2292	3	0	0	8	2303	3	163	0	166	86	350	8	444	0
Czech Republic	6759	3863	2				3865				315				2579	
Estonia	322						92	2	48		50	34	156		190	
Germany	75672	46138	476		657	7114	54385	769	2034		2803				18484	
Russia	10731	7594	0	0	0	0	7594	0	538	0	538	60	2539	0	2599	0
Serbia and Montenegro	4224	3227	62	0	0	20	3309	12	282	0	294	445	176	0	621	
Tunisia	4932	4803	0	0	0	0	4803	19	110	0	129					0
Turkey	24492	18643					18643	399	2047		2446	2304	1099		3403	

Table B.4.6

**Prevalence per million population, unadjusted***prevalent patients on December 31, by established therapy*

	Total	Haemodialysis					Peritoneal dialysis				Transplant			Missing		
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver		Tx, type unknown	Total Tx
	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp
Bosnia-Herzegovina	365.0						309.0				7.3				29.7	19.2
Croatia	656.5	516.6	0.7	0.0	0.0	1.8	519.1	0.7	36.7	0.0	37.4	19.4	78.9	1.8	100.1	0.0
Czech Republic	662.6	378.7	0.2				378.9				30.9				252.8	
Estonia	245.0						68.0	1.5	35.4		37.0	25.1	115.1		140.0	
Germany	919.0						660.0				34.0				224.0	
Russia	73.0	51.7	0.0	0.0	0.0	0.0	51.7	0.0	3.7	0.0	3.7	0.4	17.3	0.0	17.7	0.0
Serbia and Montenegro	396.6	303.0	5.8	0.0	0.0	1.9	310.7	1.1	26.5	0.0	27.6	41.8	16.5	0.0	58.3	
Tunisia	509.8	496.5	0.0	0.0	0.0	0.0	496.5	2.0	11.3	0.0	13.3					0.0
Turkey	361.0	275.0					275.0	5.9	30.2		36.1	34.0	16.2		50.2	



Table B.4.7

**Percentage of established therapy, unadjusted***prevalent patients on December 31*

	Total	Haemodialysis					Peritoneal dialysis				Transplant				Missing		
		Hospital/ centre	Home	HD, type unknown	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD, type unknown	Total PD	Living	Cadaver	Tx, type unknown	Total Tx		
	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%
Bosnia-Herzegovina	100.0						84.6				2.0					8.1	5.3
Croatia	100.0	78.7	0.1	0.0	0.0	0.3	79.1	0.1	5.6	0.0	5.7	3.0	12.0	0.3	15.2	0.0	
Czech Republic	100.0	57.1	0.0				57.2				4.7				38.2		
Estonia	100.0						27.7	0.6	14.5		15.1	10.2	47.0		57.2		
Germany	100.0						72.0				4.0				24.0		
Russia	100.0	70.8	0.0	0.0	0.0	0.0	70.8	0.0	5.0	0.0	5.0	0.6	23.7	0.0	24.2	0.0	
Serbia and Montenegro	100.0	76.4	1.5	0.0	0.0	0.5	78.3	0.3	6.7	0.0	7.0	10.5	4.2	0.0	14.7		
Tunisia	100.0	97.4	0.0	0.0	0.0	0.0	97.4	0.4	2.2	0.0	2.6						0.0
Turkey	100.0	76.1					76.1	1.6	8.4		10.0	9.4	4.5		13.9		

Table B.4.8  
**Renal transplants, number and percentage**  
*by donor type*

	Total		Living								Cadaver		Donor type unknown	
	N	%	Related		Unrelated		Living, type unknown		Living, All		N	%	N	%
			N	%	N	%	N	%	N	%				
Bosnia-Herzegovina														
Croatia **	444	100.0	83	18.7	3	0.7	0	0.0	86	19.4	350	78.8	8	1.8
Czech Republic *	325	100.0					18	5.5	18	5.5	307	94.5		
Estonia **	190	100.0							34	17.9	156	82.1		
Germany *	2346	100.0							382	16.3	1964	83.7		
Russia *	459	100.0	16	3.5	0	0.0	0	0.0	16	3.5	443	96.5	0	0.0
Serbia and Montenegro **	621	100.0	436	70.2	9	1.5	0		445	71.7	176	28.3	0	0.0
Tunisia	37	100.0	20	54.0	0	0.0	0	0.0	20	54.0	17	46.0	0	0.0
Turkey **	3403	100.0	1935	84.0	125	5.4	244	10.6	2304	100.0	1099	32.3		

\* These countries presented number of transplants in the year 2001

\*\* These countries presented prevalent patients living on a functioning graft on December 31